[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 202
1. Carvi y Nievas MN: Volume assessment of intracranial large meningiomas and considerations about their microsurgical and clinical management. Neurol Res; 2007 Dec;29(8):787-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The seven most employed microsurgical strategies and five important factors influencing the patient's outcome (tumor location, grade of peritumoral brain swelling, grade of brain atrophy, entrapment of neurovascular structures and the management of the vascular infused fluid volume) were individually analysed.
  • A complete resection was achieved in 39 patients and was not influenced by the tumor volume.
  • Twelve of 24 patients with deep located tumors and entrapped neurovascular structures presented accentuated brain swelling.
  • CONCLUSION: Tumor volume assessment allows an improved meningioma size differentiation.
  • Despite the large volume of the tumors in this series, satisfactory resection was still possible using single-stage procedures.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cerebral Angiography / methods. Female. Humans. Imaging, Three-Dimensional / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neuronavigation / methods. Neurosurgical Procedures. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553216.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL: Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol; 2007 Jan;177(1):131-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Between 1980 and 2003, 236 patients with clinical stage IIA-III nonseminomatous germ cell tumors underwent post-chemotherapy retroperitoneal lymph node dissection.
  • Patients with increased preoperative tumor markers (alpha-fetoprotein greater than 15 ng/ml and/or beta-human chorionic gonadotropin greater than 2.2 U/ml) were excluded from study resulting in 198 patients for analysis.
  • RESULTS: The clinical stage of testis cancer was IIA in 17, IIB in 49, IIC in 83 and III in 49 patients.
  • Of the cases of recurrence 21 (46.7%) were in those of clinical stage III, 18 (40%) stage IIC and 6 (11.8%) stage IIB disease.
  • The most frequent site of recurrence was the chest (32, 49%), followed by the abdomen (14, 22%), supraclavicular lymph nodes (8, 13%), brain (5, 8%) and other sites (5, 8%).
  • CONCLUSIONS: Based on the recurrence pattern we propose stage specific surveillance guidelines for the followup of patients after post-chemotherapy retroperitoneal lymph node dissection.
  • [MeSH-minor] Adolescent. Adult. Humans. Male. Middle Aged. Population Surveillance. Retroperitoneal Space. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162023.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Standish LJ, Torkelson C, Hamill FA, Yim D, Hill-Force A, Fitzpatrick A, Olsen M, Schildt S, Sweet E, Wenner CA, Martzen MR: Immune defects in breast cancer patients after radiotherapy. J Soc Integr Oncol; 2008;6(3):110-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to evaluate the immune status of women with stage I-III breast cancer after receiving external beam radiotherapy (RT).
  • Fourteen stage I-III, estrogen or progesterone receptor-positive or-negative (FER/PR +\-), postsurgical breast cancer patients undergoing a standard course of chemotherapy and radiation were studied.
  • Complete blood counts (CBC) with differential, phagocytic activity, natural killer (NK) cell functional activity, and tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma cytokine activity were measured immediately before and for the six weeks following the completion of radiation therapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(2):99-105 [14572152.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Oct;18(10):921-4 [6218994.001]
  • [Cites] Anticancer Res. 1983 Jan-Feb;3(1):41-5 [6600907.001]
  • [Cites] Int J Cancer. 1984 Sep 15;34(3):303-8 [6592154.001]
  • [Cites] Eur J Surg Oncol. 1985 Jun;11(2):137-41 [3891413.001]
  • [Cites] Cancer. 1986 Jan 15;57(2):245-50 [3484657.001]
  • [Cites] Cancer Immunol Immunother. 1986;21(1):6-11 [3632917.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):1944-8 [2224791.001]
  • [Cites] Indian J Pathol Microbiol. 1991 Jan;34(1):1-6 [1665479.001]
  • [Cites] Cancer. 1992 Nov 15;70(10):2475-83 [1423177.001]
  • [Cites] Int J Immunopharmacol. 1993 Aug;15(6):745-50 [8407056.001]
  • [Cites] J Immunol Methods. 1995 Sep 25;185(2):209-16 [7561131.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):235-42 [8664034.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):880-8 [10074922.001]
  • [Cites] Breast Cancer Res Treat. 2005 May;91(2):163-71 [15868444.001]
  • [Cites] Radiother Oncol. 2005 Sep;76(3):334-9 [16024123.001]
  • [Cites] Brain Behav Immun. 2005 Nov;19(6):521-5 [15890493.001]
  • [Cites] Rays. 2005 Apr-Jun;30(2):197-203 [16294914.001]
  • [Cites] Acta Oncol. 2006;45(2):175-83 [16546863.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2759-66 [16675568.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):691-8 [11597810.001]
  • [Cites] Altern Med Rev. 2000 Feb;5(1):4-27 [10696116.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Oct;17(5):325-37 [16931107.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):821-7 [12060116.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2919-25 [12767108.001]
  • (PMID = 19087768.001).
  • [ISSN] 1715-894X
  • [Journal-full-title] Journal of the Society for Integrative Oncology
  • [ISO-abbreviation] J Soc Integr Oncol
  • [Language] ENG
  • [Grant] United States / NCCIH NIH HHS / AT / AT001998-01A10003; United States / NCCIH NIH HHS / AT / U19 AT001998; United States / NCCIH NIH HHS / AT / 5 U19-AT001998; United States / NCCIH NIH HHS / AT / U19 AT001998-01A10003
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Cytokines; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ NIHMS157524; NLM/ PMC2845471
  •  go-up   go-down


Advertisement
4. Unterberger I, Kuchukhidze G, Walser G, Dobesberger J, Koppelstaetter F, Ortler M, Bauer R, Trinka E: Successful surgery in late onset epilepsy with tuberous sclerosis complex. Epileptic Disord; 2009 Mar;11(1):75-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis complex (TSC) is a multisystem genetic disorder with variable phenotypic expression, caused by mutations in one of the two tumor suppressor genes, TSC1 or TSC2.
  • Careful multi-stage presurgical evaluation, including prolonged video-EEG-monitoring, cerebral high resolution MRI, ictal and interictal [99m Tc]HMPAO-SPECT, [18 F]FDG-PET and further invasive recordings with subdural and depth electrodes led to the identification of an epileptogenic tuber with concordant seizure onset zone in the right neocortical temporal lobe.
  • [MeSH-minor] Age of Onset. Brain / physiopathology. Brain / surgery. Electroencephalography. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures / methods. Positron-Emission Tomography / methods. Radiopharmaceuticals. Technetium Tc 99m Exametazime. Tomography, Emission-Computed, Single-Photon / methods. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Epileptic Disord. 2009 Mar;11(1):80-1 [19349255.001]
  • (PMID = 19349254.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 3B744AG22N / Technetium Tc 99m Exametazime
  •  go-up   go-down


5. Virgintino D, Errede M, Girolamo F, Capobianco C, Robertson D, Vimercati A, Serio G, Di Benedetto A, Yonekawa Y, Frei K, Roncali L: Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development. J Neuropathol Exp Neurol; 2008 Jan;67(1):50-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development.
  • During brain development and blood-brain barrier (BBB) differentiation the expression of P-glycoprotein (P-gp) may complement the protective function of the placental barrier against xenobiotic substances.
  • The protocol was then tested on adult human brains as a BBB-P-gp tissue-specific control and for double labeling with anti-P-gp and the astroglia marker glial fibrillary acidic protein (GFAP).
  • At the earliest examined stage, 12 weeks of gestation (wg), P-gp was detectable as diffuse cytoplasmic labeling of the endothelial cells lining the primary cortex microvessels.
  • [MeSH-major] Blood-Brain Barrier / embryology. Blood-Brain Barrier / metabolism. Brain / embryology. Brain / metabolism. Human Development / physiology. P-Glycoprotein / physiology
  • [MeSH-minor] Adult. Age Factors. Carcinoma / metabolism. Caveolins / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Female. Fetus. Fibrosarcoma / metabolism. Glial Fibrillary Acidic Protein / metabolism. Humans. Male. Middle Aged. Vimentin / metabolism


6. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong EK, Lee JS: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res; 2005 Apr 15;11(8):3032-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A subset of patients with adenocarcinoma of the lung who had never smoked cigarettes showed excellent tumor responses to gefitinib therapy.
  • EXPERIMENTAL DESIGN: Eligible patients had no smoking history, stage IIIB or IV adenocarcinoma, Eastern Cooperative Oncology Group performance status 0 to 2, and adequate organ functions.
  • Of 10 patients with evaluable brain metastases, 7 had objective responses in both intracranial and extracranial lesions, 1 had stable disease in the brain and dramatic response in the extracranial lesions, and 2 had progressive disease in both sites.
  • CONCLUSIONS: Gefitinib showed very dramatic antitumor activity, even in the brain, with unprecedented survival outcome in never-smoker adenocarcinoma patients.
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / prevention & control. Brain Neoplasms / secondary. Disease Progression. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Skin Diseases / chemically induced. Smoking. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837758.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


7. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography showed an 18 x 16 cm right pelvic tumor, with both cystic and solid components, ascites and bilateral massive pleural effusion.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Adjuvant chemotherapy with carboplatin and paclitaxel was prescribed postoperatively, but the malignancy was not controlled due to lung, brain and vulva metastases.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Carcinoembryonic Antigen / metabolism. Combined Modality Therapy. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Necrosis. Vulvar Neoplasms / secondary


8. Khamly KK, Thursfield VJ, Fay M, Desai J, Toner GC, Choong PF, Ngan SY, Powell GJ, Thomas DM: Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer; 2009 Jul 15;125(2):426-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For brain tumors and thyroid cancers, which are primarily treated surgically, there were no gender-related differences in outcomes.
  • Although no differences in tumor stage or compliance were identified, male AYAs experienced less toxicity and lower response rates to chemotherapy (p = 0.008).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Young Adult


9. Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN: Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer; 2006 Jun 1;106(11):2445-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated.
  • METHODS: Patients with histologically confirmed, unresectable, American Joint Committee on Cancer Stage IV melanoma were enrolled in an open-label, Phase II study.
  • The primary endpoints were tumor response and safety.
  • RESULTS: Thirty-five patients (median age, 55 years) with Stage IV melanoma and a median of 3 metastatic sites were enrolled and received a median of 1 cycle (i.e., 8 weeks) of therapy (range, 0-6 cycles).
  • Eleven patients (31%) (95% confidence interval, 16% to 47%) had an objective tumor response, including 3 with clinical complete response durations of 6 months, 20 months, and 32+ months and 8 with partial responses.
  • No patient developed brain metastases while receiving study treatment.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Follow-Up Studies. Humans. Interferon-alpha / administration & dosage. Male. Middle Aged. Polyethylene Glycols. Recombinant Proteins. Remission Induction. Survival Rate

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 American Cancer Society.
  • (PMID = 16639739.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


10. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN: Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol; 2009 May;12(4):447-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder.
  • Changes in brain-derived neurotrophic factor (BDNF) levels and cytokines are potential candidates.
  • BDNF was decreased only in those patients in the late stage of bipolar disorder.
  • When levels were compared between patients at early and late stages of illness, there was a significant decrease in BDNF and IL-6 in the later stage of BD compared to the early stage.
  • Inversely, TNF-alpha showed a significant increase at the later stage.
  • Failure of inflammatory defences in the late stage of the disorder may account for reduction in BDNF and continued elevations in cytokines; thus these may have the potential to serve as markers of illness progression in BD.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18771602.001).
  • [ISSN] 1469-5111
  • [Journal-full-title] The international journal of neuropsychopharmacology
  • [ISO-abbreviation] Int. J. Neuropsychopharmacol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Brain-Derived Neurotrophic Factor; 0 / Cytokines; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


11. Wada Y, Takahashi R, Yanagihara C, Nishimura Y: Paradoxical cerebral embolism as the initial symptom in a patient with ovarian cancer. J Stroke Cerebrovasc Dis; 2007 Mar-Apr;16(2):88-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain magnetic resonance imaging showed an acute multiple infarction, and a simultaneous acute pulmonary embolism was observed.
  • Transesophageal echocardiography showed a patent foramen ovale, multidetector row computed tomography an ovarian tumor and infarction of the spleen, whereas multidetector row computed tomography venography showed right iliac vein compression by the ovarian tumor.
  • The diagnosis was stage Ic ovarian cancer.
  • [MeSH-minor] Adult. Constriction, Pathologic. Female. Hemianopsia / etiology. Humans. Iliac Vein / pathology. Iliac Vein / radiography. Magnetic Resonance Imaging. Pulmonary Embolism / complications. Splenic Infarction / complications. Splenic Infarction / radiography. Tomography, Spiral Computed

  • Genetic Alliance. consumer health - Embolism.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689401.001).
  • [ISSN] 1532-8511
  • [Journal-full-title] Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  • [ISO-abbreviation] J Stroke Cerebrovasc Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Wang ZX, Chen YY, Li BA, Tan GW, Liu XY, Shen SH, Zhu HW, Wang HD: Decreased pygopus 2 expression suppresses glioblastoma U251 cell growth. J Neurooncol; 2010 Oct;100(1):31-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results demonstrated that tumor grade exhibited a positive correlation with overexpression of Pygo2.
  • Results showed that inhibition of Pygo2 expression resulted in inhibited cell proliferation and invasiveness, as well as increased cell cycle arrest at the G(1) stage and decreased expression of the Wnt target gene cyclin D1.
  • [MeSH-major] Brain Neoplasms / metabolism. Down-Regulation / physiology. Gene Expression Regulation, Neoplastic / physiology. Glioblastoma / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. RNA, Small Interfering / pharmacology
  • [MeSH-minor] Adult. Analysis of Variance. Bromodeoxyuridine. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Cyclin D / metabolism. Female. Flow Cytometry. Humans. Indoles. Male. Middle Aged. Time Factors. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2002 Apr 5;109(1):47-60 [11955446.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Biol Cell. 2005 Mar;97(3):185-96 [15715524.001]
  • [Cites] Development. 2002 Jun;129(11):2565-76 [12015286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] Int J Oncol. 2007 Feb;30(2):357-63 [17203217.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] Genes Dev. 2000 Aug 1;14 (15):1837-51 [10921899.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2216-23 [16609037.001]
  • [Cites] Development. 2002 Sep;129(17):4089-101 [12163411.001]
  • [Cites] Nature. 2000 Sep 28;407(6803):530-5 [11029007.001]
  • [Cites] Bioessays. 2008 May;30(5):448-56 [18404694.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):367-73 [11988739.001]
  • [Cites] Neurochem Res. 2009 Jul;34(7):1278-88 [19148749.001]
  • [Cites] J Neurobiol. 2005 Sep 15;64(4):458-75 [16041741.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Nat Cell Biol. 2004 Jul;6(7):626-33 [15208637.001]
  • [Cites] J Neurooncol. 2008 May;87(3):271-7 [18217212.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):R64-7 [15668160.001]
  • [Cites] Cell. 1997 Mar 21;88(6):789-99 [9118222.001]
  • [Cites] Acta Oncol. 2006;45(4):375-88 [16760173.001]
  • [Cites] Cancer Lett. 2007 Nov 18;257(2):172-81 [17709179.001]
  • [Cites] Curr Biol. 2004 Mar 23;14(6):458-66 [15043810.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Nature. 2000 Sep 28;407(6803):527-30 [11029006.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Genomics. 2004 Aug;84(2):398-405 [15234002.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):615-24 [17083476.001]
  • [Cites] Genes Dev. 1995 May 1;9(9):1087-97 [7744250.001]
  • [Cites] Genes Dev. 1994 Jan;8(1):118-30 [8288125.001]
  • [Cites] Breast Cancer Res. 2001;3(6):351-5 [11737884.001]
  • [Cites] Dev Biol. 2003 Sep 1;261(1):132-48 [12941625.001]
  • [Cites] Cancer Lett. 2002 Sep 8;183(1):95-101 [12049819.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):979-85 [10023673.001]
  • [Cites] Cancer Gene Ther. 2009 Apr;16(4):351-61 [18949017.001]
  • (PMID = 20204459.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Indoles; 0 / Intracellular Signaling Peptides and Proteins; 0 / PYGO2 protein, human; 0 / RNA, Small Interfering; 0 / beta Catenin; 47165-04-8 / DAPI; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


13. Yang SY, Kim DG, Lee SH, Chung HT, Paek SH, Hyun Kim J, Jung HW, Han DH: Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer; 2008 Apr 15;112(8):1780-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases.
  • BACKGROUND: The aim of the current study was to determine whether a pulmonary resection and gamma-knife radiosurgery (GKRS) protocol is superior to GKRS alone in selected patients with stage IV nonsmall-cell lung cancer (NSCLC).
  • METHODS: The authors performed a retrospective case-control study of 232 consecutive patients with newly diagnosed NSCLC from January 1998 to December 2005 and screened them to identify a study cohort in which all patients had thoracic stage I or II, Karnofsky performance status >or= 70, no extracranial metastases, and 1-3 synchronous brain metastases of less than 3 cm, and were treated with GKRS (n=31).
  • One-year and 5-year local brain tumor control rates were 97.1% and 93.5%, respectively.
  • CONCLUSIONS: The pulmonary resection and GKRS protocol could prolong survival in patients with thoracic stage I or II NSCLC, no extracranial metastases, and a limited number of small synchronous brain metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300239.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Lai WH, Ho JC, Lee YK, Ng KM, Au KW, Chan YC, Lau CP, Tse HF, Siu CW: ROCK inhibition facilitates the generation of human-induced pluripotent stem cells in a defined, feeder-, and serum-free system. Cell Reprogram; 2010 Dec;12(6):641-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human-induced pluripotent stem cells (iPSCs) generated from human adult somatic cells through reprogramming hold great promises for future regenerative medicine.
  • These human iPSCs expressed a panel of pluripotency markers including stage-specific embryonic antigen (SSEA)-4, tumor-rejection antigen (TRA)-1-60, TRA-1-81, and alkaline phosphatase, while maintaining normal karyotypes and the exogenous reprogramming factors being silenced.
  • [MeSH-minor] Adult. Animals. Cell Differentiation. Cell Line. Fibroblasts / cytology. Fibroblasts / physiology. Humans. Karyotyping. Mice

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stem Cells Dev. 2011 Mar;20(3):503-14 [20632795.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):971-4 [11581665.001]
  • [Cites] Biol Reprod. 2004 Mar;70(3):837-45 [14627547.001]
  • [Cites] Science. 1998 Nov 6;282(5391):1145-7 [9804556.001]
  • [Cites] Nat Med. 2005 Feb;11(2):228-32 [15685172.001]
  • [Cites] Stem Cells. 2005 Mar;23(3):306-14 [15749925.001]
  • [Cites] Stem Cells. 2005 Mar;23(3):315-23 [15749926.001]
  • [Cites] Nat Methods. 2005 Mar;2(3):185-90 [15782187.001]
  • [Cites] Lancet. 2005 May 7-13;365(9471):1636-41 [15885296.001]
  • [Cites] Nat Biotechnol. 2006 Feb;24(2):185-7 [16388305.001]
  • [Cites] Nat Biotechnol. 2007 Jun;25(6):681-6 [17529971.001]
  • [Cites] EMBO J. 2007 Nov 14;26(22):4744-55 [17948051.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Stem Cells. 2007 Dec;25(12):3029-37 [17823238.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1917-20 [18029452.001]
  • [Cites] Nat Biotechnol. 2008 Jan;26(1):101-6 [18059259.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):141-6 [18157115.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):39-49 [18371333.001]
  • [Cites] Int J Dev Biol. 2008;52(4):353-63 [18415935.001]
  • [Cites] PLoS One. 2008;3(8):e3001 [18714354.001]
  • [Cites] Circulation. 2001 Jun 19;103(24):2885-90 [11413075.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Sep;9(9):725-9 [18698329.001]
  • [Cites] Hum Reprod. 2009 Mar;24(3):580-9 [19056770.001]
  • [Cites] Bioessays. 2009 Mar;31(3):336-43 [19260014.001]
  • [Cites] Science. 2009 May 8;324(5928):797-801 [19325077.001]
  • [Cites] Cell Stem Cell. 2009 Jun 5;4(6):472-6 [19481515.001]
  • [Cites] Hum Reprod. 2009 Oct;24(10):2468-76 [19602515.001]
  • [Cites] Cell Stem Cell. 2009 Oct 2;5(4):353-7 [19796614.001]
  • [Cites] Stem Cells. 2009 Nov;27(11):2667-74 [19697349.001]
  • [Cites] Cell Biol Int. 2009 Dec;33(12):1268-73 [19524692.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2992-3000 [19839055.001]
  • [Cites] Ann N Y Acad Sci. 2010 Feb;1188:52-7 [20201886.001]
  • [Cites] Nat Protoc. 2010 Mar;5(3):588-94 [20203673.001]
  • [Cites] Stem Cell Rev. 2010 Mar;6(1):96-107 [20012714.001]
  • [Cites] Proteomics. 2002 Sep;2(9):1187-203 [12362336.001]
  • (PMID = 20858051.001).
  • [ISSN] 2152-4998
  • [Journal-full-title] Cellular reprogramming
  • [ISO-abbreviation] Cell Reprogram
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; EC 2.7.11.1 / rho-Associated Kinases
  • [Other-IDs] NLM/ PMC2993021
  •  go-up   go-down


15. Haris M, Gupta RK, Husain N, Hasan KM, Husain M, Narayana PA: Measurement of DTI metrics in hemorrhagic brain lesions: possible implication in MRI interpretation. J Magn Reson Imaging; 2006 Dec;24(6):1259-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of DTI metrics in hemorrhagic brain lesions: possible implication in MRI interpretation.
  • PURPOSE: To understand the biological basis of possible mechanisms responsible for increased fractional anisotropy (FA) in different stages of hemorrhage and hemorrhagic brain lesions.
  • MATERIALS AND METHODS: A total of 19 patients with cerebral hemorrhage (CH), five patients with hemorrhagic infarct (HI), and nine patients with hemorrhagic brain tumor (HBT) were prospectively evaluated with diffusion tensor imaging (DTI) and the FA and mean diffusivity (MD) was quantified.
  • RESULTS: High FA (>0.20) with low MD in the acute and early subacute stage and low FA (<0.20) with increased MD in the late subacute and chronic stage of CH and HI were observed.
  • CONCLUSION: Intact RBCs entangled within fibrin mesh appear to be responsible for high FA in hemorrhagic brain lesions.
  • [MeSH-major] Algorithms. Brain / pathology. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Intracranial Hemorrhages / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17096394.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Rolls A, Shechter R, London A, Segev Y, Jacob-Hirsch J, Amariglio N, Rechavi G, Schwartz M: Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med; 2008 Aug 19;5(8):e171
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND FINDINGS: We inflicted spinal cord injury in adult mice and examined the effects of CSPG on the recovery process.
  • We found that CSPG plays a key role during the acute recovery stage after spinal cord injury in mice.
  • Using the chimeric mice we found that the immediate inhibition of CSPG production caused a dramatic effect on the spatial organization of the infiltrating myeloid cells around the lesion site, decreased insulin-like growth factor 1 (IGF-1) production by microglia/macrophages, and increased tumor necrosis factor alpha (TNF-alpha) levels.
  • The distinction made in this study between the beneficial role of CSPG during the acute stage and its deleterious effect at later stages emphasizes the need to retain the endogenous potential of this molecule in repair by controlling its levels at different stages of post-injury repair.

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Neurosci. 2007 Jan;8(1):57-69 [17180163.001]
  • [Cites] Mol Neurobiol. 2006 Dec;34(3):221-42 [17308354.001]
  • [Cites] Glia. 2002 Jul;39(1):85-97 [12112378.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7526-35 [12196576.001]
  • [Cites] J Neurol Sci. 2002 Oct 15;202(1-2):13-23 [12220687.001]
  • [Cites] Brain. 2007 Apr;130(Pt 4):940-53 [17314203.001]
  • [Cites] Brain Res. 2007 Jul 23;1159:8-17 [17572395.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):867-83 [17459594.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2277-82 [17540856.001]
  • [Cites] Nat Neurosci. 2007 Dec;10(12):1544-53 [18026096.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):4106-14 [10805752.001]
  • [Cites] Curr Opin Neurobiol. 2001 Feb;11(1):89-94 [11179877.001]
  • [Cites] J Neurosci Res. 2001 Jan 1;63(1):90-7 [11169618.001]
  • [Cites] Neurobiol Dis. 2001 Feb;8(1):11-8 [11162236.001]
  • [Cites] Brain Res. 2001 Mar 2;893(1-2):104-12 [11222998.001]
  • [Cites] J Cereb Blood Flow Metab. 2001 Jul;21(7):828-34 [11435795.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jul;60(7):676-85 [11444796.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Dec;60(12):1198-207 [11764092.001]
  • [Cites] J Neurosci. 2002 Apr 1;22(7):2792-803 [11923444.001]
  • [Cites] Nature. 2002 Apr 11;416(6881):636-40 [11948352.001]
  • [Cites] Restor Neurol Neurosci. 2001;19(3-4):189-98 [12082221.001]
  • [Cites] J Neuroimmunol. 2003 Jan;134(1-2):25-34 [12507769.001]
  • [Cites] Glia. 2003 Apr 1;42(1):36-45 [12594735.001]
  • [Cites] Biochem Soc Trans. 2003 Apr;31(2):335-6 [12653631.001]
  • [Cites] J Neurosci. 2003 Mar 15;23(6):2284-93 [12657687.001]
  • [Cites] Brain Res Dev Brain Res. 2003 May 14;142(2):111-9 [12711362.001]
  • [Cites] Mol Neurobiol. 2003 Apr;27(2):153-62 [12777685.001]
  • [Cites] Trends Neurosci. 2003 Oct;26(10):555-63 [14522149.001]
  • [Cites] Nat Rev Neurosci. 2004 Feb;5(2):146-56 [14735117.001]
  • [Cites] J Neurosci. 2004 Mar 3;24(9):2143-55 [14999065.001]
  • [Cites] J Neurosci. 2004 Mar 3;24(9):2182-90 [14999069.001]
  • [Cites] Neurobiol Aging. 2004 May-Jun;25(5):663-74 [15172746.001]
  • [Cites] Aging Cell. 2004 Aug;3(4):169-76 [15268750.001]
  • [Cites] Eur J Neurosci. 2004 Oct;20(8):1973-83 [15450076.001]
  • [Cites] J Dent Res. 2004 Nov;83(11):880-5 [15505240.001]
  • [Cites] Anal Biochem. 1982 Oct;126(1):131-8 [7181105.001]
  • [Cites] Neuron. 1990 Oct;5(4):463-9 [2206534.001]
  • [Cites] Adv Exp Med Biol. 1992;313:329-40 [1442268.001]
  • [Cites] J Clin Invest. 1993 Jun;91(6):2368-77 [8514850.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):182-6 [7969452.001]
  • [Cites] Nature. 1995 Apr 13;374(6523):647-50 [7715705.001]
  • [Cites] Exp Neurol. 1996 Nov;142(1):103-10 [8912902.001]
  • [Cites] J Neurosci Methods. 1997 Mar;72(1):57-63 [9128169.001]
  • [Cites] Endocrinology. 1997 Jul;138(7):3024-34 [9202248.001]
  • [Cites] Exp Neurol. 1997 Dec;148(2):587-603 [9417835.001]
  • [Cites] J Neurobiol. 1998 Jan;34(1):41-54 [9469617.001]
  • [Cites] Nat Med. 1998 Jul;4(7):814-21 [9662373.001]
  • [Cites] J Immunol. 1998 Sep 1;161(5):2465-72 [9725245.001]
  • [Cites] Nat Med. 1999 Jan;5(1):49-55 [9883839.001]
  • [Cites] Exp Neurol. 1999 Aug;158(2):351-65 [10415142.001]
  • [Cites] Metab Brain Dis. 2004 Dec;19(3-4):393-411 [15554430.001]
  • [Cites] Congenit Anom (Kyoto). 2004 Dec;44(4):181-8 [15566408.001]
  • [Cites] Int Immunopharmacol. 2005 Jan;5(1):185-93 [15589480.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11961-72 [15655247.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Apr;48(2):234-9 [15850662.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):145-56 [15998793.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3114-22 [16020513.001]
  • [Cites] Mol Cell Neurosci. 2006 Jan;31(1):149-60 [16297637.001]
  • [Cites] J Neurosci. 2006 Feb 8;26(6):1730-8 [16467521.001]
  • [Cites] Mol Psychiatry. 2006 Apr;11(4):327-35 [16491130.001]
  • [Cites] FASEB J. 2006 Apr;20(6):714-6 [16473887.001]
  • [Cites] J Neurotrauma. 2006 May;23(5):635-59 [16689667.001]
  • [Cites] Nat Med. 2006 Jul;12(7):829-34 [16783372.001]
  • [Cites] J Neurosci. 2006 Sep 27;26(39):9841-50 [17005848.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):16021-6 [17043238.001]
  • [Cites] J Neurochem. 2006 Nov;99(4):1176-87 [17018025.001]
  • [Cites] Nat Neurosci. 2006 Dec;9(12):1463-4 [17128280.001]
  • [Cites] Brain. 2006 Dec;129(Pt 12):3249-69 [17071951.001]
  • [Cites] Glia. 2007 Feb;55(3):294-302 [17096403.001]
  • (PMID = 18715114.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Chondroitin Sulfate Proteoglycans; 0 / Nerve Growth Factors; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ PMC2517615
  •  go-up   go-down


17. Lutgendorf SK, DeGeest K, Sung CY, Arevalo JM, Penedo F, Lucci J 3rd, Goodheart M, Lubaroff D, Farley DM, Sood AK, Cole SW: Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun; 2009 Feb;23(2):176-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Motivated by previous indications that beta-adrenergic signaling can regulate tumor cell gene expression in model systems, we sought to determine whether similar dynamics occur in primary human ovarian cancer.
  • DNA microarray analyses of 10 ovarian carcinomas identified 266 human transcripts that were differentially expressed in tumors from patients with elevated biobehavioral risk factors (high depressive symptoms and low social support) relative to grade- and stage-matched tumors from low-risk patients.
  • Consistent with increased beta-adrenergic signaling, high biobehavioral risk patients also showed increased intra-tumor concentrations of norepinephrine (but no difference in plasma norepinephrine).
  • [MeSH-minor] Activating Transcription Factors / genetics. Activating Transcription Factors / metabolism. Adult. Aged. Aged, 80 and over. Chromatography, High Pressure Liquid. Cyclic AMP Response Element-Binding Protein / genetics. Cyclic AMP Response Element-Binding Protein / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. NF-kappa B / genetics. NF-kappa B / metabolism. Neoplasms / metabolism. Norepinephrine / blood. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors

  • Genetic Alliance. consumer health - Depression.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes. 2002 Mar;51(3):734-42 [11872674.001]
  • [Cites] Biol Psychiatry. 2008 Aug 15;64(4):266-72 [18440494.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42669-79 [12213813.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1920-5 [12578963.001]
  • [Cites] Biochem Pharmacol. 2003 May 1;65(9):1489-94 [12732361.001]
  • [Cites] Bioinformatics. 2003 Sep 22;19(14):1808-16 [14512352.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4514-21 [14555525.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2190-2 [14570955.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1757-64 [14996737.001]
  • [Cites] Brain Behav Immun. 2004 May;18(3):231-7 [15050650.001]
  • [Cites] Arch Gen Psychiatry. 1982 Mar;39(3):295-300 [7065840.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2424-30 [2548081.001]
  • [Cites] Arch Gen Psychiatry. 1994 May;51(5):411-22 [8179465.001]
  • [Cites] Nucleic Acids Res. 1996 Jan 1;24(1):238-41 [8594589.001]
  • [Cites] Scand J Immunol. 1996 Jun;43(6):640-5 [8658053.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1745-54 [8895521.001]
  • [Cites] Cell. 1997 Apr 4;89(1):73-82 [9094716.001]
  • [Cites] Annu Rev Biochem. 1997;66:807-22 [9242925.001]
  • [Cites] Int J Psychophysiol. 1998 Mar;28(2):157-66 [9545653.001]
  • [Cites] Mol Cell. 1998 Apr;1(5):661-71 [9660950.001]
  • [Cites] Science. 1999 Jan 29;283(5402):655-61 [9924018.001]
  • [Cites] Biochem Pharmacol. 1999 Jun 15;57(12):1391-7 [10353260.001]
  • [Cites] Brain Behav Immun. 1999 Jun;13(2):109-23 [10373276.001]
  • [Cites] J Psychosom Res. 2004 Oct;57(4):353-8 [15518669.001]
  • [Cites] Bioinformatics. 2005 Mar15;21(6):803-10 [15374858.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):305-13 [15954082.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7105-13 [16192594.001]
  • [Cites] Psychosom Med. 2005 Nov-Dec;67(6):846-54 [16314588.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):240-8 [16498446.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2744-9 [16381019.001]
  • [Cites] Nat Med. 2006 Aug;12(8):939-44 [16862152.001]
  • [Cites] Arch Intern Med. 2006 Sep 18;166(16):1756-62 [16983055.001]
  • [Cites] Biol Psychiatry. 2006 Oct 15;60(8):819-24 [16712805.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10357-64 [17079456.001]
  • [Cites] Biol Psychol. 2007 Jan;74(1):20-5 [16860921.001]
  • [Cites] Biochem Pharmacol. 2007 Mar 15;73(6):814-23 [17196553.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14094-100 [17353197.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):29919-26 [17716980.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10389-96 [17974982.001]
  • [Cites] Brain Behav Immun. 2008 Jan;22(1):15-21 [17697764.001]
  • [Cites] Nat Rev Neurosci. 2008 Jan;9(1):46-56 [18073775.001]
  • [Cites] Genome Biol. 2007;8(9):R189 [17854483.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):808-15 [12209725.001]
  • (PMID = 18550328.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA88293; United States / NCI NIH HHS / CA / R01 CA116778; United States / NCI NIH HHS / CA / R01 CA116778-03; United States / NCI NIH HHS / CA / R01 CA116778-01A2; United States / NCI NIH HHS / CA / R01 CA110793-05; United States / NCI NIH HHS / CA / R01 CA116778-02; United States / NCI NIH HHS / CA / R01 CA109298; United States / NCI NIH HHS / CA / R01 CA110793; United States / NCI NIH HHS / CA / R01 CA104825; United States / NCI NIH HHS / CA / R01 CA109298-05; United States / NCI NIH HHS / CA / R21 CA088293
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Activating Transcription Factors; 0 / Cyclic AMP Response Element-Binding Protein; 0 / NF-kappa B; X4W3ENH1CV / Norepinephrine
  • [Other-IDs] NLM/ NIHMS95450; NLM/ PMC2677379
  •  go-up   go-down


18. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M: Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol; 2010 Dec;21(12):2348-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of and survival following brain metastases among women with inflammatory breast cancer.
  • BACKGROUND: The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC).
  • PATIENTS AND METHODS: Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified.
  • Cumulative incidence of brain metastases was computed.
  • Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases.
  • Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively.
  • Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively.
  • Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19-1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43-2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant.
  • Median survival following a diagnosis of brain metastases was 6 months.
  • CONCLUSION: Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening.


19. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A: Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol; 2007 Oct;107(1):58-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our results have revealed that serum concentration of cancer antigens, including CA 125, CA 15-3, and CEA are higher in patients with Stage III endometrial cancer as compared to those with Stage I.
  • In addition, we have shown that the expression of CA 125, AFP, and ACTH is elevated in women with tumor grade 3 vs. grade 1.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1976 Nov 15;126(6):638-47 [984136.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4059-66 [15381683.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):85-103 [6693055.001]
  • [Cites] Vopr Onkol. 1987;33(8):99-102 [2820150.001]
  • [Cites] Am J Obstet Gynecol. 1988 Feb;158(2):399-402 [2449079.001]
  • [Cites] Cancer Immunol Immunother. 1982;14(2):105-9 [6965225.001]
  • [Cites] Prim Care. 1992 Sep;19(3):607-20 [1410066.001]
  • [Cites] Annu Rev Nutr. 1994;14:495-533 [7946531.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(3):167-72 [9119882.001]
  • [Cites] Tumour Biol. 1997;18(4):241-9 [9218009.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4B):3083-6 [9329607.001]
  • [Cites] Immunology. 1998 May;94(1):88-93 [9708191.001]
  • [Cites] J Endocrinol. 1998 Jul;158(1):137-44 [9713335.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):470-7 [10502722.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4508-15 [15705794.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):92-8 [15904949.001]
  • [Cites] Cell Mol Neurobiol. 2005 Jun;25(3-4):743-57 [16075388.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 May;95(1-5):71-4 [15939586.001]
  • [Cites] BMC Cancer. 2005;5:110 [16117833.001]
  • [Cites] Cell Mol Immunol. 2004 Jun;1(3):199-204 [16219168.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] Hum Reprod. 2005 Dec;20(12):3510-3 [16055459.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):63-73 [16116035.001]
  • [Cites] Cancer Biol Ther. 2006 Jan;5(1):71-7 [16322684.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2376-81 [16639730.001]
  • [Cites] Gynecol Oncol. 2006 Sep;102(3):440-6 [16510175.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2763-77 [17116732.001]
  • [Cites] Future Oncol. 2006 Dec;2(6):733-41 [17155900.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):84-93 [17063306.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):384-92 [17198749.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2139-42 [17434921.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):363-77 [16364689.001]
  • [Cites] J Endocrinol. 2006 Apr;189(1):45-55 [16614380.001]
  • [Cites] Proc AMIA Symp. 2000;:759-63 [11079986.001]
  • [Cites] J Endocrinol. 2002 May;173(2):219-38 [12010630.001]
  • [Cites] Recent Prog Horm Res. 2002;57:435-55 [12017556.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):28-33 [12079296.001]
  • [Cites] Oncogene. 2002 Aug 8;21(34):5213-23 [12149643.001]
  • [Cites] Neuro Endocrinol Lett. 2002 Jul;23 Suppl 2:43-7 [12163847.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1281-91 [12553432.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1913-26 [12759248.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):567-71 [15297205.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Eur Cytokine Netw. 2004 Apr-Jun;15(2):99-104 [15319167.001]
  • [Cites] Zentralbl Gynakol. 1980;102(21):1209-12 [6163266.001]
  • (PMID = 17659325.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA117452-04S1; United States / NCI NIH HHS / CA / CA117452-03; United States / NCI NIH HHS / CA / R01 CA098642-03; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / R01 CA108990; United States / NCI NIH HHS / CA / U01 CA117452; United States / NCI NIH HHS / CA / R01 CA098642-02; United States / NCI NIH HHS / CA / U01 CA117452-04S1; United States / NCI NIH HHS / CA / R03 CA136019-01; United States / NCI NIH HHS / CA / R03 CA136019; United States / NCI NIH HHS / CA / U01 CA117452-03; United States / NCI NIH HHS / CA / U01 CA117452-01; United States / NCI NIH HHS / CA / CA117452-04; United States / NCI NIH HHS / CA / R01 CA098642-01A1; United States / NCI NIH HHS / CA / R01 CA108990-02; United States / NCI NIH HHS / CA / CA117452-02; United States / NCI NIH HHS / CA / U01 CA117452-02; United States / NCI NIH HHS / CA / U01 CA117452-04; United States / NCI NIH HHS / CA / R01 CA108990-04; United States / NCI NIH HHS / CA / R01 CA098642-04; United States / NCI NIH HHS / CA / CA136019-01; United States / NCI NIH HHS / CA / R01 CA108990-01A1; United States / NCI NIH HHS / CA / R01 CA108990-03; United States / NCI NIH HHS / CA / CA117452-01
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 9002-62-4 / Prolactin
  • [Other-IDs] NLM/ NIHMS32488; NLM/ PMC2777971
  •  go-up   go-down


20. Liang KL, Jiang RS, Lin JC, Chiu YJ, Shiao JY, Su MC, Hsin CH: Central nervous system infection in patients with postirradiated nasopharyngeal carcinoma: a case-controlled study. Am J Rhinol Allergy; 2009 Jul-Aug;23(4):417-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From September 1989 to May 2006, we conducted a retrospective study of 18 postirradiated NPC patients with CNS infection including brain abscess, cavernous sinus thrombosis, epidural abscess, and meningitis in our institute.
  • During the same period, 18 NPC patients without CNS infection who were matched for tumor stage, age, and gender with the study group were randomly selected from the cancer registry at our hospital and enrolled as the control group.
  • RESULTS: The local tumor relapse rate, nasopharyngeal radiotherapy dose, and skull base osteoradionecrosis were all significantly higher in patients with CNS infection (p = 0.003, 0.011, and 0.001, respectively).
  • [MeSH-minor] Adult. Aged. Biopsy. Dose-Response Relationship, Radiation. Endoscopy. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Taiwan / epidemiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671259.001).
  • [ISSN] 1945-8924
  • [Journal-full-title] American journal of rhinology & allergy
  • [ISO-abbreviation] Am J Rhinol Allergy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


21. Kim JH, Kim HS, Sung CW, Kim KJ, Kim CH, Lee KY: Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer; 2008 Feb;59(2):270-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 35-year-old woman was diagnosed with stage IV non-small cell lung cancer with brain metastasis.
  • With an object of controlling the increased intracranial pressure, we initially performed a craniotomy with tumor removal, followed by whole brain irradiation.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Brain Neoplasms / radiography. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Diagnosis, Differential. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Infant, Newborn. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Pregnancy Trimester, First. Pregnancy Trimester, Second. Radiation-Sensitizing Agents. Ribonucleotide Reductases / antagonists & inhibitors. Tomography, X-Ray Computed


22. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol; 2005 Sep 1;23(25):6043-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
  • We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression.
  • PATIENTS AND METHODS: A total of 56 patients with progressive stage IV melanoma were enrolled onto the study.
  • Tumor regression was seen in lung, liver, brain, lymph nodes, and subcutaneous sites.
  • [MeSH-minor] Adult. Aged. Antigens, CD. CTLA-4 Antigen. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Male. Middle Aged. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1993 Oct 1;151(7):3489-99 [8397258.001]
  • [Cites] Immunity. 1994 Aug;1(5):405-13 [7882171.001]
  • [Cites] Immunity. 1994 Dec;1(9):793-801 [7534620.001]
  • [Cites] Science. 1995 Nov 10;270(5238):985-8 [7481803.001]
  • [Cites] Nature. 1987 Jul 16-22;328(6127):267-70 [3496540.001]
  • [Cites] Science. 1970 Sep 11;169(3950):1042-9 [4194660.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2866-76 [15295006.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5673-7 [14634073.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):666-75 [12951585.001]
  • [Cites] J Immunol. 2002 Aug 15;169(4):1852-8 [12165509.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] J Exp Med. 1996 Jun 1;183(6):2533-40 [8676074.001]
  • [Cites] J Exp Med. 1996 Jun 1;183(6):2541-50 [8676075.001]
  • [Cites] Immunity. 1997 Dec;7(6):885-95 [9430233.001]
  • [Cites] Nat Med. 1998 Mar;4(3):321-7 [9500606.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10067-71 [9707601.001]
  • [Cites] Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23 [9815296.001]
  • [Cites] Diabetes. 1999 Mar;48(3):652-7 [10078573.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5813-20 [10229815.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):355-66 [10430624.001]
  • [Cites] J Immunother. 2004 Nov-Dec;27(6):478-9 [15534492.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):741-50 [15613700.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] Genes Immun. 2000 Feb;1(3):170-84 [11196709.001]
  • [Cites] Annu Rev Immunol. 2001;19:565-94 [11244047.001]
  • [Cites] J Exp Med. 2001 Jun 4;193(11):1311-8 [11390438.001]
  • [Cites] Eur J Immunol. 2002 Feb;32(2):366-73 [11807776.001]
  • [Cites] Nat Rev Immunol. 2001 Dec;1(3):220-8 [11905831.001]
  • [Cites] Curr Opin Immunol. 2002 Jun;14(3):391-6 [11973140.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):611-8 [12087419.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):389-400 [12093005.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):349-56 [12843797.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):337-42 [12612581.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Science. 1990 Jun 15;248(4961):1349-56 [2113314.001]
  • [Cites] J Exp Med. 1991 Mar 1;173(3):759-62 [1847724.001]
  • [Cites] J Exp Med. 1991 Mar 1;173(3):721-30 [1847722.001]
  • [Cites] J Immunol. 1988 May 15;140(10):3324-30 [2834436.001]
  • [Cites] J Exp Med. 1991 Sep 1;174(3):561-9 [1714933.001]
  • [Cites] J Immunol. 1992 Jul 15;149(2):380-8 [1320641.001]
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):5875-7 [16087939.001]
  • (PMID = 16087944.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010763-01; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Cancer Vaccines; 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ NIHMS10153; NLM/ PMC1473965
  •  go-up   go-down


23. Khalil EM: Treatment results of adults and children with medulloblastoma NCI, Cairo University experience. J Egypt Natl Canc Inst; 2008 Jun;20(2):175-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Between 1997 and 2004, 67 patients were treated in the National cancer Institute- Cairo University; 51 pediatric patients with a median age of 7 years and 16 adult patients with a median age of 25 years.
  • All patients underwent primary surgical resection; near total resection in 25% , Subtotal resection in 61% ; with tumor residual < 1.5cm(2) in 49% compared to 51% with > 1.5cm(2) residual tumor and 14% , had biopsy only.
  • All patients were treated by craniospinal radiotherapy (RT); with a median dose of 34Gy to the whole brain, 54Gy to the posterior fossa and 32Gy to the spinal axis.
  • The median interval between surgery and RT was 45 days and 38 days for the pediatric and adult groups respectively.
  • The median duration of RT was 54 days and 52 days for pediatric and adult patients respectively.
  • RESULTS: For the pediatric and adult patients, the 5- and 7-year overall and disease-free survival rates were 89% & 78% vs. 84% & 56% and 80% & 68% vs. 79% & 52% respectively.
  • Ninety percent (9/10) of the pediatric relapses were of the high risk group (8 received no chemotherapy) and took place within 2 years; similarly all adult relapses were of the high risk group; three relapses took place after 2 years.
  • For adult patients; only the risk category was a significant prognostic factor with 5-year disease-free survival rate of 100% vs. 40% for low and high risk respectively (p=0.03).
  • On multivaiate analysis only the risk category and the T-stage were significant prognostic factors for disease free survival for the pediatric age group (p=0.042 and 0.031).
  • CONCLUSION: Survival rates of medulloblastoma pediatric patients were better than the adult ones.
  • Late relapses, lateral tumor location and shorter median follow up were noted in adult patients.
  • Advanced tumor stage, metastases at presentation, limited tumor resection were powerful prognostic factors among the pediatric patients.
  • In addition, high risk category was shown to be a prognostic factor for both pediatric and adult patients.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029474.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Shah H, Anker CJ, Bogart J, Graziano S, Shah CM: Brain: the common site of relapse in patients with pancoast or superior sulcus tumors. J Thorac Oncol; 2006 Nov;1(9):1020-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain: the common site of relapse in patients with pancoast or superior sulcus tumors.
  • PURPOSE: We conducted a retrospective analysis to determine the occurrence of brain metastasis with superior sulcus tumors.
  • Twenty-nine out of 685 patients (4%) had a diagnosis of Pancoast or superior sulcus tumor.
  • Regarding stage at presentation: seven patients had stage IIB, two had stage IIIA, 16 had stage IIIB, and four had stage IV.
  • The total occurrence of brain metastasis is seven out of 29 patients (24%).
  • Two patients (stage IV) had brain metastasis at the time of presentation and five patients (stage IIB-III) developed brain metastasis at a median time of 10 months after the diagnosis.
  • Stage associated with brain metastasis after diagnosis is two patients for stage IIB, two for stage IIIA, and one for stage IIIB.
  • For the 25 patients with stage IIB to stage III disease, nine (36%) developed distant metastasis after definitive therapy.
  • Out of these nine patients, five (55%) developed brain metastasis.
  • Histology for seven patients with brain metastasis was four of seven with adenocarcinoma, two of seven with squamous cell carcinoma, and one of seven with NSCLC.
  • CONCLUSION: Brain metatasis may be relatively common at diagnosis.
  • The brain is the frequent site of failure for superior sulcus tumors.
  • We recommend careful surveillance for brain metastasis during and after the therapy.
  • We also recommend obtaining brain imaging prior to surgery in patients receiving induction therapy for the primary tumor.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Lung Neoplasms / pathology. Pancoast Syndrome / epidemiology. Pancoast Syndrome / secondary
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Incidence. Lung / anatomy & histology. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409988.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. German-Fattal M, Lecerf F, Sabbagh F, Maurois P, Durlach J, Bac P: Neuroprotective gene profile in the brain of magnesium-deficient mice. Biomed Pharmacother; 2008 Apr-May;62(4):264-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroprotective gene profile in the brain of magnesium-deficient mice.
  • In the current study, we explore endothelial cell activation, inflammation and cell death induced in the brain of adult mice by Mg-deficient diet.
  • METHODS AND RESULTS: Neither TNFalpha, substance P, sTNFRI, sTNFRII proteins (ELISA), nor TNFalpha, adherence molecules and prolactin mRNAs, nor NK1R (immunohistochemistry on brain sections) were up-regulated.
  • Using cDNA assay, we showed a neuroprotective, anti-apoptotic and neurotrophic gene expression profile in the brain at early stage of hypomagnesemia.
  • As a model for neuronal injury, mild sound stimulation of Mg-deficient mice without convulsive seizures triggers neither the release of substance P, nor the development of an inflammatory process or cell death in the brain.
  • CONCLUSION: Our results suggest that Mg-deficiency in mice favours the development of a neuroprotective environment in the brain.
  • [MeSH-major] Brain / metabolism. Gene Expression Profiling. Magnesium Deficiency / metabolism
  • [MeSH-minor] Animals. Apoptosis. Female. Immunohistochemistry. Inflammation / etiology. Intercellular Adhesion Molecule-1 / analysis. Intercellular Adhesion Molecule-1 / genetics. Interleukin-2 / analysis. Magnesium / metabolism. Mice. Prolactin / genetics. Receptors, Cannabinoid / genetics. Receptors, Granulocyte Colony-Stimulating Factor / genetics. Receptors, Tumor Necrosis Factor / analysis

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18400454.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Receptors, Cannabinoid; 0 / Receptors, Granulocyte Colony-Stimulating Factor; 0 / Receptors, Tumor Necrosis Factor; 126547-89-5 / Intercellular Adhesion Molecule-1; 9002-62-4 / Prolactin; I38ZP9992A / Magnesium
  •  go-up   go-down


26. Allen J, Donahue B, Mehta M, Miller DC, Rorke LB, Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G, Muraszko K, Puccetti D, Prados M, Chan KW: A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1006-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
  • METHODS AND MATERIALS: Eligibility criteria included age >3 years at diagnosis, medulloblastoma with either high M stage and/or >1.5 cm(2) postoperative residual disease, and all patients with noncerebellar PNET.
  • Treatment was initiated with five alternating monthly cycles of CHT (A [cisplatin, cyclophosphamide, etoposide, and vincristine], B [carboplatin and etoposide], A, B, and A) followed by hyperfractionated CSRT (40 Gy) with a boost to the primary tumor (72 Gy) given in twice-daily 1-Gy fractions.
  • No significant differences were detected in subset analysis related to response to CHT, site of primary tumor, postoperative residual disease, or M stage.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):279-85 [10030250.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] Cancer J. 2004 Nov-Dec;10(6):386-90 [15701271.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):727-34 [15763649.001]
  • [Cites] Australas Radiol. 2005 Aug;49(4):298-303 [16026436.001]
  • [Cites] Acta Oncol. 2005;44(6):554-62 [16165914.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):711-6 [15927408.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79 [10661332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1287-94 [11483340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Feb;8(2):219-26 [7085377.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):2001-6 [6627214.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):649-53 [3258630.001]
  • [Cites] J Clin Oncol. 1989 Jun;7(6):754-60 [2715805.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Fall;12(3):297-300 [2173440.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2755-62 [8402500.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):371-8 [7836091.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1377-83 [7751882.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2247-54 [7666082.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1155-61 [8985038.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):798-804 [9264364.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):15-24 [9300735.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • (PMID = 19356859.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA003888-44; United States / NCI NIH HHS / CA / U10 CA003888; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA003888-44
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS128135; NLM/ PMC2739055
  •  go-up   go-down


27. Ohwada S, Izumi M, Kawate S, Hamada K, Toya H, Togo N, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol; 2007 Feb;37(2):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of stage III and IV adrenocortical carcinoma.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumor usually diagnosed at an advanced stage on invasion of or adherence to adjacent organs.
  • We report surgical outcome of stage III and IV ACCs.
  • METHODS: ACCs from seven patients at clinical stage II (n = 1), III (n = 4), or IV (n = 2) were resected.
  • RESULTS: The pathological stage was stage III in five patients and stage IV in two patients.
  • The estimated 3-year disease-free and overall survivals for stage III were 20% and 40%, respectively, with a median follow-up of 32 months (range, 11-58).
  • The 3-year disease-free and overall survivals for stage III and IV were 14.3% and 28.6%, respectively.
  • Loco-regional, intra-abdominal lymph node, peritoneum, bone, brain recurrences were also seen in one patient each.
  • CONCLUSIONS: Resection for stage III, IV ACCs affords the possibility of negative margins, acceptable peri-operative morbidity and mortality, and prolongs survival in selected patients.
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis. Vena Cava, Inferior / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277000.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


28. Kouyialis AT, Boviatsis EI, Karampelas IK, Korfias S, Korkolopoulou P, Sakas DE: Primitive supratentorial neuroectodermal tumor in an adult. J Clin Neurosci; 2005 May;12(4):492-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive supratentorial neuroectodermal tumor in an adult.
  • Total removal of the tumour was achieved in a two-stage procedure.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Neuroectodermal Tumors, Primitive / pathology. Supratentorial Neoplasms
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods. Neuroglia / pathology. Review Literature as Topic

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925794.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


29. Wright G, Shawcross D, Olde Damink SW, Jalan R: Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis; 2007 Dec;22(3-4):375-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension.
  • BACKGROUND: In acute liver failure (ALF), it is unclear whether the systemic inflammatory response associated with intracranial hypertension is related to brain cytokine production.
  • AIM: To determine the relationship of brain cytokine production with severity of intracranial hypertension in ALF patients.
  • In the ALF patients studied longitudinally, brain proinflammatory cytokine production was associated with uncontrolled ICP.
  • CONCLUSION: Our results provide novel data supporting brain production of cytokines in patients with uncontrolled intracranial hypertension indicating activation of the inflammatory cascade in the brain.
  • Also, the appearance of these cytokines in the jugular bulb catheter may indicate a compromised blood brain barrier at this late stage.
  • [MeSH-major] Brain / immunology. Cytokines / biosynthesis. Intracranial Hypertension / etiology. Liver Failure, Acute / immunology
  • [MeSH-minor] Adult. Ammonia / metabolism. Cross-Sectional Studies. Hepatic Encephalopathy / etiology. Humans. Interleukin-1beta / biosynthesis. Interleukin-6 / biosynthesis. Tumor Necrosis Factor-alpha / biosynthesis

  • Genetic Alliance. consumer health - Intracranial Hypertension.
  • Hazardous Substances Data Bank. Ammonia .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1989 Mar;96(3):885-91 [2914649.001]
  • [Cites] Life Sci. 1999;64(21):1941-53 [10353592.001]
  • [Cites] J Hepatol. 2001 Jun;34(6):825-31 [11451165.001]
  • [Cites] J Hepatol. 2004 Oct;41(4):613-20 [15464242.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2941-7 [9399938.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2641-7 [9389725.001]
  • [Cites] J Hepatol. 1999 Oct;31(4):771-6 [10551405.001]
  • [Cites] Minerva Anestesiol. 1989 Apr;55(4):205-7 [2615995.001]
  • [Cites] J Hepatol. 2002 Oct;37(4):536-8 [12217609.001]
  • [Cites] Lymphokine Cytokine Res. 1992 Dec;11(6):293-8 [1477182.001]
  • [Cites] Liver Transpl. 2001 Mar;7(3):274-8 [11244172.001]
  • [Cites] Hepatology. 1998 Feb;27(2):369-76 [9462633.001]
  • [Cites] J Hepatol. 1996 Aug;25(2):145-51 [8878774.001]
  • [Cites] Ann Neurol. 1991 Jan;29(1):21-5 [1996875.001]
  • [Cites] Neurochem Pathol. 1987 Feb-Apr;6(1-2):1-12 [3306479.001]
  • [Cites] J Hosp Infect. 2003 Feb;53(2):144-6 [12586576.001]
  • [Cites] Lancet. 1993 Oct 9;342(8876):898-9 [8105168.001]
  • [Cites] J Clin Invest. 1948 Jul;27(4):476-83 [16695568.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):247-54 [14739095.001]
  • [Cites] Ann Surg. 1993 Jul;218(1):3-9 [8328827.001]
  • [Cites] J Cereb Blood Flow Metab. 1989 Oct;9(5):717-20 [2777938.001]
  • [Cites] Clin Chim Acta. 1968 Oct;22(2):183-6 [5687085.001]
  • [Cites] J Clin Invest. 1991 Apr;87(4):1360-6 [2010549.001]
  • [Cites] J Pharmacol Exp Ther. 1999 May;289(2):668-75 [10215638.001]
  • [Cites] Hepatology. 1999 Mar;29(3):648-53 [10051463.001]
  • [Cites] Hepatology. 1991 Feb;13(2):376-9 [1847353.001]
  • [Cites] Acta Neuropathol. 1992;85(1):93-100 [1285500.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):755-64 [12949721.001]
  • [Cites] Hepatology. 2000 Oct;32(4 Pt 1):734-9 [11003617.001]
  • [Cites] Transplantation. 2003 Jun 27;75(12):2034-9 [12829907.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1338-46 [15521003.001]
  • [Cites] Gastroenterology. 1995 Dec;109(6):1907-16 [7498656.001]
  • [Cites] Gastroenterology. 1989 Aug;97(2):439-45 [2490426.001]
  • [Cites] Exp Brain Res. 1999 Apr;125(3):255-64 [10229016.001]
  • [Cites] Prog Liver Dis. 1970;3:282-98 [4908702.001]
  • [Cites] J Neuroimmunol. 1997 Oct;79(1):22-8 [9357443.001]
  • [Cites] Lancet. 1999 Oct 2;354(9185):1164-8 [10513710.001]
  • [Cites] Arch Surg. 1993 Jun;128(6):677-82 [8503773.001]
  • [Cites] Metab Brain Dis. 2002 Dec;17(4):437-44 [12602519.001]
  • (PMID = 17899343.001).
  • [ISSN] 0885-7490
  • [Journal-full-title] Metabolic brain disease
  • [ISO-abbreviation] Metab Brain Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 7664-41-7 / Ammonia
  •  go-up   go-down


30. Monzo M, Moreno I, Artells R, Ibeas R, Navarro A, Moreno J, Hernandez R, Granell M, Pie J: Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett; 2006 Feb 20;233(1):117-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients.
  • Although Shh has been shown to be overexpressed in brain, pancreas, gastric and lung cancers, its role in the development of colorectal cancer has not been examined.
  • We used real-time quantitative PCR to assess Shh mRNA expression levels in tumor and matched normal tissue from 57 colorectal cancer patients and correlated the results with patient clinicopathological characteristics.
  • Shh expression levels were higher in tumor tissue than in normal tissue from the same patient (P=0.00001).
  • Higher levels of Shh expression were associated with early stage disease (P=0.02).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hedgehog Proteins. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16473672.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / SHH protein, human; 0 / Trans-Activators
  •  go-up   go-down


31. McDaniel JC, Belury M, Ahijevych K, Blakely W: Omega-3 fatty acids effect on wound healing. Wound Repair Regen; 2008 May-Jun;16(3):337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Physiological events in the initial inflammatory stage of cutaneous wound healing influence subsequent stages.
  • Proinflammatory cytokines coordinate molecular and cellular processes during the inflammatory stage.
  • Proinflammatory cytokines interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha were quantified in blister fluid at 5 and 24 hours after creation.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1987 Apr 1;138(7):2137-42 [3494060.001]
  • [Cites] J Nutr. 2002 Dec;132(12):3740-3 [12468616.001]
  • [Cites] Nature. 1990 Jul 19;346(6281):274-6 [2374592.001]
  • [Cites] J Nutr. 1991 Apr;121(4):547-55 [2007907.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):835-70 [12843410.001]
  • [Cites] Lipids. 2003 Apr;38(4):343-52 [12848278.001]
  • [Cites] Intensive Care Med. 2003 Sep;29(9):1472-81 [12897994.001]
  • [Cites] Wound Repair Regen. 2004 Mar-Apr;12(2):235-43 [15086775.001]
  • [Cites] J Burn Care Rehabil. 2004 Mar-Apr;25(2):149-60 [15091141.001]
  • [Cites] Adv Data. 2004 May 27;(343):1-19 [15188733.001]
  • [Cites] J Health Soc Behav. 1983 Dec;24(4):385-96 [6668417.001]
  • [Cites] J Immunol. 1986 Nov 1;137(9):2848-52 [3093584.001]
  • [Cites] Am J Vet Res. 1998 Jul;59(7):859-63 [9659552.001]
  • [Cites] Nutrition. 1998 Jul-Aug;14(7-8):627-33 [9684267.001]
  • [Cites] Arch Gen Psychiatry. 1999 May;56(5):450-6 [10232300.001]
  • [Cites] J Nutr. 1999 Oct;129(10):1791-8 [10498749.001]
  • [Cites] Herz. 2004 Nov;29(7):673-85 [15580322.001]
  • [Cites] Adv Data. 2004 Nov 8;(348):1-6 [15587902.001]
  • [Cites] Curr Pharm Des. 2005;11(8):1017-30 [15777251.001]
  • [Cites] Lipids Health Dis. 2005;4:14 [16011805.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6 Suppl):1467S-1476S [16841856.001]
  • [Cites] Brain Behav Immun. 2006 Nov;20(6):590-6 [16730942.001]
  • [Cites] Lymphokine Res. 1990 Winter;9(4):465-73 [2151047.001]
  • [Cites] Biochim Biophys Acta. 1991 Nov 12;1095(3):187-95 [1958693.001]
  • [Cites] J Clin Invest. 1992 Jun;89(6):1734-40 [1601984.001]
  • [Cites] Psychoneuroendocrinology. 1994;19(4):313-33 [8047637.001]
  • [Cites] Am J Clin Nutr. 1996 Jan;63(1):116-22 [8604658.001]
  • [Cites] J Nutr. 1996 Jun;126(6):1515-33 [8648424.001]
  • [Cites] Lipids. 1996 Mar;31 Suppl:S23-31 [8729089.001]
  • [Cites] Cytokine. 1996 Jul;8(7):548-56 [8891436.001]
  • [Cites] Proc Soc Exp Biol Med. 2000 Jan;223(1):88-95 [10632966.001]
  • [Cites] Wound Repair Regen. 2000 Mar-Apr;8(2):83-96 [10810034.001]
  • [Cites] Forensic Sci Int. 2000 Sep 11;113(1-3):251-64 [10978634.001]
  • [Cites] Br J Nutr. 2002 Jan;87 Suppl 1:S59-67 [11895155.001]
  • [Cites] J Invest Dermatol. 2002 Apr;118(4):692-8 [11918718.001]
  • [Cites] Proc Nutr Soc. 2002 Aug;61(3):345-58 [12296294.001]
  • [Cites] N Engl J Med. 1989 Feb 2;320(5):265-71 [2783477.001]
  • (PMID = 18471252.001).
  • [ISSN] 1524-475X
  • [Journal-full-title] Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
  • [ISO-abbreviation] Wound Repair Regen
  • [Language] ENG
  • [Grant] United States / NINR NIH HHS / NR / 1 F31 NR009134-01; United States / NINR NIH HHS / NR / NR009134-03; United States / NINR NIH HHS / NR / F31 NR009134-01; United States / NINR NIH HHS / NR / F31 NR009134-02; United States / NINR NIH HHS / NR / NR009134-01; United States / NINR NIH HHS / NR / F31 NR009134; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NINR NIH HHS / NR / F31 NR009134-03; United States / NINR NIH HHS / NR / NR009134-02
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1alpha; 0 / Interleukin-1beta; 0 / Tumor Necrosis Factor-alpha; 25167-62-8 / Docosahexaenoic Acids; AAN7QOV9EA / Eicosapentaenoic Acid
  • [Other-IDs] NLM/ NIHMS73456; NLM/ PMC2967211
  •  go-up   go-down


32. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med; 2008 Jan 22;5(1):e8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patients who are more likely to benefit.
  • METHODS AND FINDINGS: Based on preclinical evidence that phosphatase and tensin homolog deleted on Chromosome 10 (PTEN) loss sensitizes tumors to the inhibition of mammalian target of rapamycin (mTOR), we conducted a proof-of-concept Phase I neoadjuvant trial of rapamycin in patients with recurrent glioblastoma, whose tumors lacked expression of the tumor suppressor PTEN.
  • We aimed to assess the safety profile of daily rapamycin in patients with glioma, define the dose of rapamycin required for mTOR inhibition in tumor tissue, and evaluate the antiproliferative activity of rapamycin in PTEN-deficient glioblastoma.
  • Although intratumoral rapamycin concentrations that were sufficient to inhibit mTOR in vitro were achieved in all patients, the magnitude of mTOR inhibition in tumor cells (measured by reduced ribosomal S6 protein phosphorylation) varied substantially.
  • Tumor cell proliferation (measured by Ki-67 staining) was dramatically reduced in seven of 14 patients after 1 wk of rapamycin treatment and was associated with the magnitude of mTOR inhibition (p = 0.0047, Fisher exact test) but not the intratumoral rapamycin concentration.
  • Tumor cells harvested from the Ki-67 nonresponders retained sensitivity to rapamycin ex vivo, indicating that clinical resistance to biochemical mTOR inhibition was not cell-intrinsic.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Proteins / antagonists & inhibitors. PTEN Phosphohydrolase / deficiency. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / physiology. Salvage Therapy. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Aged. Cell Division / drug effects. Combined Modality Therapy. Disease Progression. Feedback, Physiological. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Proto-Oncogene Proteins c-akt / metabolism. Ribosomal Protein S6 / metabolism. Signal Transduction / drug effects. TOR Serine-Threonine Kinases


33. Ulu EM, Töre HG, Bayrak A, Güngör D, Coşkun M: MRI of central nervous system abnormalities in childhood leukemia. Diagn Interv Radiol; 2009 Jun;15(2):86-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The imaging abnormalities seen in 12 patients prior to or during treatment, or within three months after completion of treatment included orbital, temporal, cerebellopontine angle, and spinal chloroma; bilateral subdural hematoma in the subacute stage; multifocal intraparenchymal hemorrhage; bilateral retinal hemorrhage and detachment; hematoma in the pons and mesencephalon; PRES (posterior reversible leukoencephalopathy syndrome); bilateral leukemic infiltration of the 3(rd), left 7(th), and 8(th) cranial nerves; and meningeal leukemia.
  • Three months after completion of treatment, three patients had CNS complications including radiation necrosis and secondary brain tumor, osteomyelitis of the L3 vertebra, and meningeal leukemia.
  • [MeSH-minor] Adolescent. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy / adverse effects. Female. Humans. Infant. Male. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517377.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


34. Sandberg DI, Ragheb J, Dunoyer C, Bhatia S, Olavarria G, Morrison G: Surgical outcomes and seizure control rates after resection of dysembryoplastic neuroepithelial tumors. Neurosurg Focus; 2005 Jun 15;18(6A):E5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors focus on the diagnostic evaluation and surgical techniques that facilitate gross-total tumor resection and subsequent freedom from seizures.
  • Thirteen patients underwent one-stage procedures, whereas five underwent two-stage procedures (implantation of monitoring electrodes followed by tumor resection), either for functional language mapping (three patients) or due to inconclusive preoperative data (two patients).
  • Intraoperative electrocorticography (ECoG) was performed in 17 patients and led to resection of the cerebral cortex beyond the tumor margins in 10 of them.
  • According to operative reports, gross-total tumor resections were achieved in all patients, but one child had minimal residual tumor on postoperative MR images that has remained stable.
  • Over a median follow-up duration of 1.6 years, all patients are seizure free and without radiographically detected tumor recurrence.
  • Excellent rates of complete tumor resection and seizure control with minimal morbidity can be attained using intraoperative ECoG and two-stage surgical procedures when appropriate.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms, Neuroepithelial / surgery. Neurosurgical Procedures / adverse effects. Seizures / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Seizures.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048291.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Nishibayashi H, Matsuda Y, Uematsu Y, Nakao N, Terada T, Itakura T: [A case of high grade astrocytoma arising in the hand area of precentral gyrus]. No To Shinkei; 2005 Jun;57(6):517-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The progressive symptoms were due to highly infiltrative and proliferative nature of the tumor arising in the focal hand area of the primary motor cortex, according to the homunculus.
  • We discuss herein the neuroimagings of the case that was considered to be in the initial stage of a malignant tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspartic Acid / analogs & derivatives. Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Motor Cortex / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Diffusion Magnetic Resonance Imaging. Drug Administration Schedule. Gadolinium DTPA. Humans. Interferon-beta / administration & dosage. Magnetic Resonance Spectroscopy. Male. Nitrosourea Compounds / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026048.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 30KYC7MIAI / Aspartic Acid; 5J49Q6B70F / Vincristine; 77238-31-4 / Interferon-beta; 997-55-7 / N-acetylaspartate; K2I13DR72L / Gadolinium DTPA; RYH2T97J77 / ranimustine
  •  go-up   go-down


36. Strobel K, Dummer R, Steinert HC, Conzett KB, Schad K, Lago MP, Soyka JD, Veit-Haibach P, Seifert B, Kalff V: Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging; 2008 Oct;35(10):1786-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.
  • PURPOSE: This study aims to compare the use of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B in chemotherapy response assessment of stage IV melanoma patients.
  • METHODS: In 25 patients with stage IV melanoma, FDG-PET/CT and S-100B after 2-3 months (three cycles) of chemotherapy was compared with baseline PET/CT and baseline S-100B.
  • In patients with clinical suspicion for brain metastases, MRI or CCT was performed.
  • Eleven patients developed brain metastases during treatment, first detected by PET/CT in two and by MRI or CCT in nine of 11 patients.
  • Appearance of brain metastases was associated with a poor survival.
  • PET/CT responders have better early survival, but this is shortlived due to late therapy failure--often with brain recurrence.
  • Additional brain MRI for therapy response assessment in such high-risk patients is mandatory to detect brain metastases missed by PET/CT.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain / diagnostic imaging. Brain / pathology. Fluorodeoxyglucose F18. Magnetic Resonance Imaging / methods. Melanoma. Nerve Growth Factors / blood. Positron-Emission Tomography / methods. S100 Proteins / blood. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Humans. Middle Aged. Outcome Assessment (Health Care) / methods. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies. S100 Calcium Binding Protein beta Subunit. Sensitivity and Specificity. Subtraction Technique. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:36S-44S [17204719.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):748-59 [14662431.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1293-300 [15051777.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4577-80 [15837974.001]
  • [Cites] Oncology. 2005;68(4-6):341-9 [16020961.001]
  • [Cites] Onkologie. 2002 Feb;25(1):74-6 [11928697.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23 (33):8362-70 [16293866.001]
  • [Cites] Semin Nucl Med. 2005 Jul;35(3):186-96 [16098292.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] Neuroradiology. 1981;22(3):123-7 [7312160.001]
  • [Cites] J Nucl Med. 2007 Oct;48(10 ):1626-32 [17873129.001]
  • [Cites] Dermatology. 1997;194(3):208-12 [9187834.001]
  • [Cites] Dermatology. 2007;215(3):192-201 [17823514.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] J Nucl Med. 2006 May;47(5):885-95 [16644760.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Pathol Oncol Res. 1999;5(3):218-22 [10491021.001]
  • [Cites] Br J Dermatol. 1999 Jun;140(6):1065-71 [10354072.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1329-37 [17623835.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):496-507 [16452561.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] Melanoma Res. 2003 Feb;13(1):45-9 [12569284.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):193-201 [7670677.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1178-87 [16505438.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Apr;21(4):611-4; discussion 614-5 [11932155.001]
  • [Cites] Eur J Cancer. 1978 Apr;14(4):327-30 [648555.001]
  • [Cites] Eur J Cancer. 1995 Oct;31A(11):1898-902 [8541129.001]
  • [Cites] Radiology. 2003 Jan;226(1):181-7 [12511688.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1144-50 [16000283.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1366-75 [17390135.001]
  • [Cites] J Nucl Med. 2007 Oct;48(10 ):1592-8 [17873138.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):607-10 [15762365.001]
  • [Cites] Melanoma Res. 1999 Feb;9(1):51-8 [10338334.001]
  • [Cites] Radiology. 2007 Aug;244(2):566-74 [17641374.001]
  • [Cites] Clin Nucl Med. 2006 Nov;31(11):707-8 [17053391.001]
  • [Cites] Br J Dermatol. 1997 Sep;137(3):381-5 [9349333.001]
  • (PMID = 18458901.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Nerve Growth Factors; 0 / Radiopharmaceuticals; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Kawai N, Okauchi M, Miyake K, Sasakawa Y, Yamamoto Y, Nishiyama Y, Tamiya T: [11C-methionine positron emission tomography in nontumorous brain lesions]. No Shinkei Geka; 2010 Nov;38(11):985-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C-methionine positron emission tomography in nontumorous brain lesions].
  • Positron emission tomography (PET) with L-[methyl-11C]methionine (MET) provides information on the metabolism of brain tumor.
  • MET uptake reflects amino acid active transport and protein synthesis and is proportional to the amount of viable tumor cells.
  • However, MET uptake can be increased as a result of increased density of inflammatory cells and disruption of the blood brain barrier (BBB) in nontumorous brain lesions.
  • From October 2005 through November 2009, 438 MET-PET studies were performed for various brain lesions at our institution.
  • Nine of 10 intracerebral hemorrhages and all 4 cerebral infarctions demonstrated mild to moderate MET uptake in or surrounding the lesions in the subacute or chronic stage after the ictus.
  • Moderately increased MET uptake was observed in all 3 patients with brain abscess.
  • We should keep in mind that high MET uptake is frequently observed in nontumorous brain lesions.
  • [MeSH-major] Brain Diseases / radionuclide imaging. Methionine / metabolism. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain Abscess / radionuclide imaging. Carbon Radioisotopes. Cerebral Infarction / radionuclide imaging. Encephalocele / radionuclide imaging. Female. Glioma / radionuclide imaging. Humans. Male. Middle Aged. Nervous System Diseases / radionuclide imaging. Optic Nerve Diseases / radionuclide imaging. Orbital Diseases / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21081810.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


38. Nicolato A, Ria A, Foroni R, Manno P, Alessandrini F, Sava T, Lupidi F, Leone P, Maluta S, Cetto GL, Gerosa M: Gamma knife radiosurgery in brain metastases from testicular tumors. Med Oncol; 2005;22(1):45-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery in brain metastases from testicular tumors.
  • To our knowledge, there are no published reports on the effectiveness of radiosurgery in the management of brain metastases from testicular nonseminomatous germ cell tumor.
  • Between April 1995 and July 2001, three patients with brain metastasis from testicular nonseminomatous germ cell tumor underwent adjuvant radiosurgery at our department.
  • The primary tumor had been surgically removed in all cases.
  • At diagnosis, one patient was stage IB and two were stage III poor risk.
  • Chemotherapy and whole brain radiotherapy were administered before radiosurgery in all cases.
  • The indications for radiosurgery were tumor volume <20 cm3, microsurgery too risky, refusal of surgery.
  • All the lesions were located in eloquent brain areas.
  • Neuroradiological follow-up invariably showed tumor growth control (complete response in two cases and partial response in one) with typically delayed post-radiosurgical imaging changes (transient in two cases and long-lasting in one).
  • In conclusion, GK seems to be highly effective and safe in brain metastases from testicular nonseminomatous germ cell tumor.
  • In cases with diffuse metastatic brain involvement, the whole brain radiotherapy preceding radiosurgery should be delivered with 1.8 Gy daily fraction to prevent the risk of long-lasting post-radiosurgical imaging changes.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / secondary. Radiosurgery / methods. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2001 Apr;55(4):232-4 [11358599.001]
  • [Cites] J Neurosurg. 2004 May;100(5):842-7 [15137603.001]
  • [Cites] Surg Neurol. 2003 Dec;60(6):506-14; discussion 514-5 [14670663.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):143-9 [12622453.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] Neurochirurgie. 1992;38(2):89-97 [1603235.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):143-6 [9711747.001]
  • [Cites] Int J Clin Oncol. 2003 Oct;8(5):289-96 [14586753.001]
  • [Cites] Cancer. 1979 Oct;44(4):1514-6 [227567.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):519-26 [12062592.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1449-54 [9193339.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1705-11 [15073860.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2182-5 [8397061.001]
  • [Cites] Neurosurgery. 1989 Feb;24(2):151-9 [2645538.001]
  • [Cites] Neurosurgery. 2002 Sep;51(3):656-65; discussion 665-7 [12188943.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):512-24 [1885968.001]
  • [Cites] Radiother Oncol. 1984 Jan;1(3):207-15 [6505257.001]
  • [Cites] Oncology. 2001;61(3):184-8 [11574772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):17-22 [1370066.001]
  • [Cites] Clin Exp Metastasis. 1994 May;12(3):226-30 [8194197.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1318-26; discussion 1326 [12762877.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):342-9 [12593621.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):544-51 [11883840.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:2-10 [9782230.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):761-3 [9525725.001]
  • [Cites] BJU Int. 1999 Mar;83(4):457-61 [10210571.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):515-24 [12507088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Br J Cancer. 1998;77(2):329-35 [9461006.001]
  • [Cites] Ital J Neurol Sci. 1997 Jun;18(3):173-5 [9241566.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):814-9 [2555732.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):12-8 [6274499.001]
  • [Cites] J Clin Oncol. 1984 Dec;2(12):1397-403 [6210350.001]
  • [Cites] Neurochirurgie. 1994;40(2):135-7 [7870248.001]
  • (PMID = 15750196.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Inoue T, Ogasawara K, Kumabe T, Jokura H, Watanabe M, Ogawa A: Minute glioma identified by 3.0 Tesla magnetic resonance spectroscopy--case report. Neurol Med Chir (Tokyo); 2005 Feb;45(2):108-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 33-year-old man presented with a minute tumor incidentally detected by magnetic resonance (MR) imaging screening.
  • 1.5 Tesla MR spectroscopy indicated normal brain tissue whereas 3.0 Tesla MR spectroscopy indicated neoplasm.
  • The tumor was completely resected.
  • 3.0 Tesla MR spectroscopy can establish the diagnosis in the early stage of glioma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722611.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


40. Vasil'ev VI, Probatova NA, Tupitsin NN, Varlamova EIu, Logvinenko OA, Rodionova EB, Kovrigina AM, Kokosadze NV, Panin MG, Gaĭduk IV, Gorbunova TV, Kondrat'eva TT, Sholokhova EN, Simonova MV, Safonova TN, Radenska-Lopovok SG: [MALT-lymphomas in Sjogren's disease]. Ter Arkh; 2006;78(1):45-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the following investigations were made: ultrasonography of the salivary glands, lymph nodes, viscera; scintigraphy; trephine biopsy of the bone marrow; myelograms; CT of the chest, abdomena and brain; tests for monoclonal immunoglobulins in the serum and light chains in urine; biopsy of the parotid gland.
  • Predominant were extranodal lymphomas of the parotid submandibular, minor salivary glands of the lip and lacrimal glands of stage I E-II E.
  • Extranodal lymphoma with nodal lesion of stage IV occurred less frequently.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphoma, B-Cell, Marginal Zone / complications. Sjogren's Syndrome / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512445.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Kim YB, Lee IJ, Kim SY, Kim JW, Yoon HI, Kim SW, Kim S, Kim YT, Suh CO, Kim GE: Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix.
  • PURPOSE: The purpose of this study was to analyze tumor heterogeneity based on tumor extent and suggest reappraisal of the system of the International Federation of Gynecology and Obstetrics (FIGO) for Stage III carcinoma of the uterine cervix from a radiotherapeutic viewpoint.
  • METHODS AND MATERIALS: Between 1986 and 2004, 407 patients with FIGO Stage III (FIGO Stage IIIa in 19 and IIIb in 388) were treated with external beam radiotherapy (RT) and high-dose rate brachytherapy.
  • All patients were reviewed with respect to tumor extent.
  • RESULTS: The complete response rate was 79.6%, and the 5-year overall survival rates for Stage IIIa and Stage IIIb carcinoma of the cervix were 82.1% and 54.8%, respectively.
  • To determine which parameters of tumor extent had an influence on prognosis for Stage IIIb patients, pelvic wall (PW) extension and hydronephrosis (HD) retained significance on multivariate analysis.
  • Stage IIIb patients were divided into three subgroups according to PW extension and HD: low risk (unilateral PW extension without HD), intermediate risk (HD without PW extension or bilateral PW extension without HD), and high risk (unilateral or bilateral PW extension with HD).
  • CONCLUSIONS: FIGO Stage III carcinoma of the cervix covers considerably heterogeneous subgroups according to tumor extent.
  • Before initiation of treatment, we suggest that physicians determine a tailored treatment policy based on tumor heterogeneity for each Stage III patient.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Brachytherapy / methods. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Chi-Square Distribution. Female. Humans. Middle Aged. Survival Rate. Treatment Outcome. Tumor Burden


42. Gil Z, Carlson DL, Gupta A, Lee N, Hoppe B, Shah JP, Kraus DH: Patterns and incidence of neural invasion in patients with cancers of the paranasal sinuses. Arch Otolaryngol Head Neck Surg; 2009 Feb;135(2):173-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with brain invasion or neurogenic tumors were excluded.
  • Intraneural invasion was found in 32% of these cases, and 34% invaded more than 1 cm distal to the tumor.
  • Neural invasion was associated with a high rate of positive margins, maxillary origin, and previous surgical treatment (P < .04) but not with stage, orbital invasion, or dural invasion.
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / pathology. Child. Female. Humans. Male. Melanoma / pathology. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Skull Base Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19221246.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Reyes-Gibby CC, Spitz MR, Yennurajalingam S, Swartz M, Gu J, Wu X, Bruera E, Shete S: Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev; 2009 Oct;18(10):2636-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many of the same inflammatory factors that promote tumor growth are also hypothesized to function as pain modulators.
  • Advanced stage of disease [odds ratio (OR), 2.34; 95% confidence interval (95% CI), 1.50-3.65; P = 0.001], age < or = 50 years (OR, 2.10; 95% CI, 1.32-3.30; P = 0.002), reports of depressed mood (OR, 3.68; 95% CI, 1.96-6.93; P = 0.001), fatigue (OR, 3.72; 95% CI, 2.36-5.87; P = 0.001), and morphine equivalent daily dose (OR, 1.02; 95% CI, 1.01-1.03) were significantly correlated with severe pain.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858273 for PMID:19773451 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1764-72 [11058619.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3262-7 [18990769.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • [Cites] Neuroreport. 2001 Jul 20;12(10):2079-84 [11447311.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):753-6 [11792966.001]
  • [Cites] J Pain Symptom Manage. 2002 Mar;23(3):239-55 [11888722.001]
  • [Cites] Neurosci Lett. 2002 Apr 19;323(1):75-7 [11911993.001]
  • [Cites] Eur Spine J. 2002 Feb;11(1):62-6 [11931066.001]
  • [Cites] Nat Neurosci. 2002 Nov;5 Suppl:1062-7 [12403987.001]
  • [Cites] J Neurosci. 2004 Feb 18;24(7):1637-45 [14973242.001]
  • [Cites] Am J Med. 2004 Mar 1;116(5):318-24 [14984817.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Neuroscience. 2004;124(4):945-52 [15026134.001]
  • [Cites] Pain. 2004 May;109(1-2):8-19 [15082121.001]
  • [Cites] Lung Cancer. 2004 Mar;43(3):247-57 [15165082.001]
  • [Cites] Eur J Neurosci. 2004 Jun;19(12):3375-81 [15217394.001]
  • [Cites] J Clin Psychiatry. 2004;65 Suppl 12:5-9 [15315471.001]
  • [Cites] Pain. 2004 Sep;111(1-2):77-83 [15327811.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Sep;63(9):901-10 [15453089.001]
  • [Cites] Qual Life Res. 2004 Oct;13(8):1369-79 [15503832.001]
  • [Cites] Brain Res. 1994 Aug 15;654(1):15-26 [7982088.001]
  • [Cites] Life Sci. 1995;57(11):1011-26 [7658909.001]
  • [Cites] Pain. 1995 May;61(2):277-84 [7659438.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9 [9096369.001]
  • [Cites] Br J Pharmacol. 1997 Jun;121(3):417-24 [9179382.001]
  • [Cites] Psychol Rev. 1998 Jan;105(1):83-107 [9450372.001]
  • [Cites] J Pain Symptom Manage. 1999 Jun;17(6):391-401 [10388244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1755-60 [15665080.001]
  • [Cites] Arthritis Res Ther. 2005;7(4):R807-16 [15987482.001]
  • [Cites] Nat Rev Neurosci. 2005 Jul;6(7):521-32 [15995723.001]
  • [Cites] J Clin Psychiatry. 2005 Aug;66(8):982-8 [16086612.001]
  • [Cites] Neuroscience. 2005;135(3):969-77 [16125859.001]
  • [Cites] Behav Brain Res. 2006 Feb 28;167(2):355-64 [16256210.001]
  • [Cites] Head Neck. 2006 Apr;28(4):313-20 [16200627.001]
  • [Cites] Neurosci Lett. 2006 Aug 14;404(1-2):154-8 [16777324.001]
  • [Cites] J Pain Symptom Manage. 2006 Aug;32(2):118-28 [16877179.001]
  • [Cites] Arthritis Rheum. 2006 Aug;54(8):2656-64 [16871547.001]
  • [Cites] Pain. 2006 Dec 15;126(1-3):294-308 [16949747.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6520-7 [17596594.001]
  • [Cites] Anesth Analg. 2007 Sep;105(3):838-47 [17717248.001]
  • [Cites] Pain. 2007 Nov;132(1-2):195-205 [17890011.001]
  • [Cites] Pain. 2007 Dec 15;133(1-3):18-28 [17407800.001]
  • [Cites] Arthritis Rheum. 2007 Dec;56(12):4015-23 [18050216.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2745-51 [18086782.001]
  • [Cites] Mol Pain. 2005;1:9 [15813997.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2236-44 [18381966.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):777-85 [18672213.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • (PMID = 19773451.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA128069; United States / NCI NIH HHS / CA / CA127219; United States / NCI NIH HHS / CA / R01 CA127219; United States / NCI NIH HHS / CA / K07 CA109043-05; United States / NCI NIH HHS / CA / CA109043-05; United States / NCI NIH HHS / CA / K07 CA109043; United States / NCI NIH HHS / CA / CA127219-04; United States / NCI NIH HHS / CA / R03 CA128069-02; United States / NCI NIH HHS / CA / CA128069; United States / NCI NIH HHS / CA / R01 CA127219-01A1; United States / NCI NIH HHS / CA / CA127219-01A1; United States / NCI NIH HHS / CA / CA128069-02; United States / NCI NIH HHS / CA / CA109043; United States / NCI NIH HHS / CA / R01 CA127219-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS140213; NLM/ PMC2759856
  •  go-up   go-down


44. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR: Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer; 2010 Nov 1;116(21):5038-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer.
  • BACKGROUND: The risk of developing brain metastases after definitive treatment of locally advanced nonsmall cell lung cancer (NSCLC) is approximately 30%-50%.
  • The risk for patients with early stage disease is less defined.
  • The cumulative incidence of brain metastases and distant metastases was estimated by using the Kaplan-Meier method.
  • A multivariate analysis assessed factors associated with the development of brain metastases.
  • RESULTS: Of 975 consecutive patients, 85% were stage I, and 15% were stage II.
  • The 5-year actuarial risk of developing brain metastases and distant metastases was 10%(95% confidence interval [CI], 8-13) and 34%(95% CI, 30-39), respectively.
  • Of patients developing brain metastases, the brain was the sole site of failure in 43%.
  • On multivariate analysis, younger age (hazard ratio [HR], 1.03 per year), larger tumor size (HR, 1.26 per cm), lymphovascular space invasion (HR, 1.87), and hilar lymph node involvement (HR, 1.18) were associated with an increased risk of developing brain metastases.
  • CONCLUSIONS: In this large series of patients treated surgically for early stage NSCLC, the 5-year actuarial risk of developing brain metastases was 10%.
  • A better understanding of predictive factors and biological susceptibility is needed to identify the subset of patients with early stage NSCLC who are at particularly high risk.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cranial Irradiation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Recurrence. Risk Factors


45. Cetingöz R, Cetinayak HO, Sen RC, Demiral AN, Akkoçlu A, Osma E, Kargi A, Oztop I, Onen A, Kinay M, Dokuz Eylül Lung Cancer Study Group: Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach. J BUON; 2006 Jan-Mar;11(1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
  • PURPOSE: To evaluate the combined modality treatment results of patients with limited-stage small cell lung cancer (SCLC), who were treated and followed by the DELCSG.
  • PATIENTS AND METHODS: Sixty-three patients with limited-stage SCLC diagnosed between April 1991 and December 2002 were included.
  • A total dose of 5000 cGy with 180-200 cGy daily fractions was given to the primary tumor and mediastinum, excluding the spinal cord after 4500 cGy.
  • During follow-up, 27 (43%) patients developed brain metastasis; among them only 3 had received PCI.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318949.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CAV protocol; VP-P protocol
  •  go-up   go-down


46. Melanoma Study Group of the Mayo Clinic Cancer Center, Celis E: Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer; 2007 Jul 1;110(1):203-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
  • METHODS: Patients with stage IV melanoma were randomized to 1 of 3 treatment arms:.
  • Exclusion criteria included pregnancy/nursing, brain metastases, and ongoing chemotherapy.
  • RESULTS: None of the 28 patients exhibited objective tumor responses or severe toxicities.
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Dendritic Cells / immunology. Epitopes / immunology. Female. Freund's Adjuvant / chemistry. Granulocyte-Macrophage Colony-Stimulating Factor / chemistry. HLA Antigens / immunology. Humans. Lymphocyte Activation / drug effects. Lymphocyte Activation / immunology. Male. Mannitol / analogs & derivatives. Mannitol / chemistry. Middle Aged. Neoplasm Staging. Oleic Acids / chemistry. Survival Analysis. Survival Rate. T-Lymphocytes, Cytotoxic / drug effects. T-Lymphocytes, Cytotoxic / immunology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. D-MANNITOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17541944.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Epitopes; 0 / GRAMLGTHTMEVTV; 0 / HLA Antigens; 0 / Oleic Acids; 0 / Oligopeptides; 0 / montanide ISA 51; 3OWL53L36A / Mannitol; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9007-81-2 / Freund's Adjuvant
  •  go-up   go-down


47. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA: Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer; 2010 Dec 1;55(6):1126-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
  • BACKGROUND: Sorafenib is an inhibitor of multiple kinases (e.g., VEGF receptors, PDGFR, FLT3, RET, BRAF, KIT) and is approved by FDA for treatment of two adult cancers.
  • In vivo sorafenib induced significant differences in event-free survival (EFS) distribution compared to control in 27 of 36 (75%) of the evaluable solid tumor xenografts and in 1 of 8 (12.5%) of the evaluable ALL xenografts.
  • Sorafenib induced tumor growth inhibition meeting criteria for intermediate activity (EFS T/C) in 15 of 34 (44%) evaluable solid tumor xenografts.
  • The primary in vivo effect for sorafenib was tumor growth inhibition, which was observed across multiple histotypes.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2004 Dec;12(6):1269-72 [15547749.001]
  • [Cites] Acta Neuropathol. 2004 Dec;108(6):467-70 [15517309.001]
  • [Cites] Leukemia. 2005 Feb;19(2):310-2 [15538400.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6861-9 [16007148.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):326-34 [16507829.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):581-6 [16880785.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1875-85 [17071608.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11851-8 [17178882.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Haematologica. 2007 Jan;92(1):27-34 [17229632.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74 [17160391.001]
  • [Cites] Leukemia. 2007 Mar;21(3):439-45 [17205056.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):886-97 [17363483.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3363-9 [17545544.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4874-81 [17699867.001]
  • [Cites] Mol Pharmacol. 2007 Sep;72(3):788-95 [17595328.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41 [18077425.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):535-48 [18026728.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):581-7 [17457854.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 6;100(3):184-98 [18230792.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):42-8 [18293383.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4572-83 [18628472.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6109-17 [18676833.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4908-14 [18676765.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3129-40 [18852116.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Mol Cancer Ther. 2008 Nov;7(11):3519-26 [19001435.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):348-50 [18573526.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6567-71 [19389879.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4263-9 [19549778.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1425-32 [20007803.001]
  • [Cites] Blood. 2010 Mar 25;115(12):2372-9 [20056794.001]
  • [Cites] Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):361-6 [21816375.001]
  • [Cites] Hematol J. 2002;3(3):157-63 [12111653.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • (PMID = 20672370.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CM / N01-CM-42216; United States / NCI NIH HHS / CA / N01CM42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ NIHMS214707; NLM/ PMC3823056
  •  go-up   go-down


48. Tariverdian N, Rücke M, Szekeres-Bartho J, Blois SM, Karpf EF, Sedlmayr P, Klapp BF, Kentenich H, Siedentopf F, Arck PC: Neuroendocrine circuitry and endometriosis: progesterone derivative dampens corticotropin-releasing hormone-induced inflammation by peritoneal cells in vitro. J Mol Med (Berl); 2010 Mar;88(3):267-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within this cohort, early stage of endometriosis were diagnosed in n = 30 and advanced stage of endometriosis in n = 8.
  • [MeSH-minor] Adult. Cells, Cultured. Cohort Studies. Female. Humans. Interleukin-10 / metabolism. Neurosecretory Systems / metabolism. Peritoneum / cytology. Phenotype. Progesterone / blood. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DYDROGESTERONE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fertil Steril. 1997 May;67(5):856-64 [9130890.001]
  • [Cites] J Reprod Immunol. 2009 Jun;80(1-2):80-90 [19375804.001]
  • [Cites] Hum Reprod Update. 2003 Jul-Aug;9(4):387-96 [12926531.001]
  • [Cites] Hum Reprod. 1991 May;6(5):699-702 [1939552.001]
  • [Cites] Fertil Steril. 1991 Apr;55(4):759-65 [2010001.001]
  • [Cites] Am J Reprod Immunol. 2008 Nov;60(5):449-61 [19238750.001]
  • [Cites] J Reprod Immunol. 2004 Jun;62(1-2):61-8 [15288182.001]
  • [Cites] Am J Reprod Immunol. 1994 Oct;32(3):180-3 [7880401.001]
  • [Cites] Am J Reprod Immunol. 1995 Jan;33(1):74-80 [7619237.001]
  • [Cites] BJOG. 2005 Aug;112(8):1096-101 [16045524.001]
  • [Cites] Fertil Steril. 1994 Oct;62(4):701-7 [7926076.001]
  • [Cites] Fertil Steril. 1992 Jun;57(6):1203-10 [1601140.001]
  • [Cites] Cytokine. 1998 Apr;10(4):313-8 [9617578.001]
  • [Cites] Brain Res. 1983 Sep 26;275(2):373-7 [6194860.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Oct 28;204(2):828-34 [7980549.001]
  • [Cites] Gut. 1996 Sep;39(3):385-92 [8949642.001]
  • [Cites] Auton Neurosci. 2000 Dec 20;85(1-3):127-32 [11189019.001]
  • [Cites] Am J Obstet Gynecol. 1992 Jul;167(1):265-70 [1442940.001]
  • [Cites] Obstet Gynecol. 2007 Sep;110(3):594-600 [17766605.001]
  • [Cites] Hum Reprod. 2006 Nov;21(11):3001-7 [16950827.001]
  • [Cites] Annu Rev Psychol. 2000;51:29-57 [10751964.001]
  • [Cites] Am J Reprod Immunol. 1996 Jun;35(6):552-7 [8792939.001]
  • [Cites] J Immunol. 2004 May 15;172(10):5893-9 [15128769.001]
  • [Cites] Fertil Steril. 1992 Aug;58(2):290-5 [1633893.001]
  • [Cites] J Psychosom Res. 2002 Jan;52(1):29-33 [11801262.001]
  • [Cites] J Assist Reprod Genet. 2003 Mar;20(3):117-21 [12735387.001]
  • [Cites] Complement Ther Nurs Midwifery. 2003 May;9(2):62-8 [12697156.001]
  • [Cites] Am J Reprod Immunol. 2004 Oct;52(4):267-75 [15494048.001]
  • [Cites] Cell Immunol. 1997 May 1;177(2):194-9 [9178647.001]
  • [Cites] Hum Reprod. 1995 Oct;10(10):2671-5 [8567790.001]
  • [Cites] Eur J Endocrinol. 1998 Feb;138(2):216-26 [9506869.001]
  • [Cites] Nat Med. 1999 Oct;5(10):1178-82 [10502822.001]
  • [Cites] Ann N Y Acad Sci. 1998 May 1;840:664-73 [9629293.001]
  • [Cites] Endocrinology. 2004 Jan;145(1):43-8 [14576187.001]
  • [Cites] Steroids. 2003 Nov;68(10-13):931-40 [14667986.001]
  • [Cites] Fertil Steril. 1997 May;67(5):817-21 [9130884.001]
  • [Cites] Dig Dis Sci. 2002 Jan;47(1):208-15 [11852879.001]
  • [Cites] Semin Immunopathol. 2007 Jun;29(2):193-210 [17621704.001]
  • [Cites] Leuk Lymphoma. 2007 Aug;48(8):1610-7 [17701593.001]
  • [Cites] Trends Immunol. 2006 Jan;27(1):32-9 [16269267.001]
  • [Cites] Am J Reprod Immunol. 1995 Dec;34(6):381-5 [8607944.001]
  • [Cites] J Psychosom Res. 1993;37(2):111-6 [8463987.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD002122 [10796864.001]
  • [Cites] Psychother Psychosom Med Psychol. 1992 Jul;42(7):242-52 [1287693.001]
  • [Cites] J Mol Med (Berl). 2006 Feb;84(2):159-67 [16389545.001]
  • [Cites] Cell Immunol. 1989 Sep;122(2):281-94 [2527616.001]
  • [Cites] J Endocrinol Invest. 1998 Jan;21(1):37-42 [9633021.001]
  • (PMID = 19898767.001).
  • [ISSN] 1432-1440
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 4G7DS2Q64Y / Progesterone; 9015-71-8 / Corticotropin-Releasing Hormone; 90I02KLE8K / Dydrogesterone
  •  go-up   go-down


49. Jiang F, Xu L, Yuan FL, Huang JF, Lu XX, Zhang XY: [Lung auto-transplantation technique in the treatment for stage III central lung cancer]. Zhonghua Yi Xue Za Zhi; 2010 May 18;90(19):1329-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung auto-transplantation technique in the treatment for stage III central lung cancer].
  • OBJECTIVE: To assess the feasibility and benefit of lung auto-transplantation technique in surgical treatment for stage III central lung cancer.
  • Since the length of resected bronchus or pulmonary artery involved by tumor was too long to perform tension-free anastomosis, we transplanted the inferior pulmonary vein to the proximal stump of the superior pulmonary vein.
  • Until Jan 2008, six of the eight patients who underwent lung autotransplantations, had been free of tumor recurrence for 7-90 months with good quality of life.
  • Another patient died of brain metastases 31 months postoperatively.
  • CONCLUSION: Lung auto-transplantation is an alternative technique for pulmonary preservation for patient with stage III centrally placed lung cancer, whose cardio-pulmonary functions is too poor to undergo pneumonectomy.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Transplantation, Autologous


50. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol; 2009 Feb;91(3):329-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed retrospectively 51 patients with recurrent high-grade glioma treated with this combination at the Henry Ford Hermelin Brain Tumor Center from 11/15/2005 to 04/01/2008.
  • Six patients (11.76%) discontinued treatment due to a treatment-emergent adverse event, including one with end-stage renal failure and another with gastric perforation.
  • The high rate of distant tumor progression suggests that tumors may adapt to inhibition of angiogenesis by increased infiltration and vascular co-option.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Glioma / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Disease-Free Survival. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2012 Feb;116(2):336-40; discussion 340 [22035270.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4705-6 [17947716.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):1981-6 [18081012.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Brain Res Brain Res Rev. 2004 Jul;45(3):143-63 [15210301.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Clin Oncol. 1999 May;17 (5):1516-25 [10334539.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Eur Radiol. 2001;11(10):2004-10 [11702135.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10 ):2897-904 [17504989.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):221-5 [17029014.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 18953493.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


51. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH: Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol; 2010 Nov;21(11):2169-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival differences among women with de novo stage IV and relapsed breast cancer.
  • BACKGROUND: The objective of this retrospective study was to determine whether differences in survival exist between women with de novo stage IV and relapsed breast cancer.
  • PATIENTS AND METHODS: Three thousand five hundred and twenty-four women with de novo stage IV or relapsed breast cancer diagnosed from 1992 to 2007 were identified.
  • Cox proportional hazards model was fitted to determine the association between metastatic disease (relapsed versus de novo) and OS after controlling for other patient/tumor characteristics.
  • RESULTS: Six hundred and forty-three (18.2%) women had de novo stage IV disease and 2881 (81.8%) had relapsed disease.
  • Median OS among patients with de novo stage IV and relapsed disease was 39.2 and 27.2 months, respectively (P < 0.0001).
  • When the multivariable model was stratified by DFI, women with relapsed disease with DFI <6 months, ≥6 months to <2 years, or ≥2 to <5 years each had a significantly higher risk of death compared with women with de novo stage IV disease.
  • CONCLUSIONS: This large cohort study provides further insight into the natural history of relapsed and de novo stage IV breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):92-8 [19933921.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):197-207 [11885995.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):44-52 [14692023.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3302-8 [15310773.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):3861-5 [476622.001]
  • [Cites] Cancer Res. 1989 Apr 15;49(8):1996-2001 [2702641.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1370-1 [1922240.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Apr;13(2):415-34 [10363138.001]
  • [Cites] Ann Surg. 2008 May;247(5):732-8 [18438108.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1696-702 [18357493.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4891-8 [18725649.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2012-9 [18641006.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Ann Oncol. 2009 Nov;20(11):1771-85 [19608616.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • (PMID = 20427349.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1K07 CA 109064
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2962259
  •  go-up   go-down


52. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H: Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology; 2007 Mar;242(3):882-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.
  • PURPOSE: To retrospectively assess possible clinical predictors of metastatic disease to the brain in patients with non-small cell lung carcinoma (NSCLC).
  • Hierarchical logistic regression was used to determine the predicted probability of metastatic disease to the brain as a function of patient age and sex and of size, cell type, peripheral versus central location, and lymph node stage of the primary NSCLC.
  • RESULTS: Ninety-five (36%) patients had evidence of metastatic disease to the brain.
  • Cell types included adenocarcinoma (136 [52%] patients), undifferentiated (68 [26%] patients), and squamous (47 [18%] patients), for which metastatic disease to the brain occurred in 43%, 41%, and 13% (P = .003) of patients, respectively.
  • The predicted probability of metastatic disease to the brain correlated positively with size of the primary tumor (P < .001), cell type (adenocarcinoma and undifferentiated vs squamous, P = .001), and lymph node stage (P < .017) but did not correlate with age, sex, or primary tumor location.
  • For primary adenocarcinoma without lymph node spread, the predicted probabilities of metastatic disease to the brain from 2- and 6-cm primary tumors were .14 (95% confidence interval: .06, .27) and .72 (95% confidence interval: .48, .88), respectively (P < .02).
  • CONCLUSION: The probability of metastatic disease to the brain from primary NSCLC is correlated with size of the primary tumor, cell type, and intrathoracic lymph node stage.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / epidemiology. Risk Assessment / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. New York / epidemiology. Prevalence. Risk Factors. Sex Distribution

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229875.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Nishinari K, Wolosker N, Yazbek G, Zerati AE, Nishimoto IN, Puech-Leão P: Arterial reconstructions associated with the resection of malignant tumors. Clinics (Sao Paulo); 2006 Aug;61(4):339-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: When trunk arteries are affected by malignant neoplasia, and surgical treatment involving tumor and arterial resection is used, the vascular reconstruction must be performed immediately to avoid ischemia in the brain and large tissue masses.
  • The objective of this study was to analyze the results obtained with the treatment of patients with malignant neoplasia who underwent tumor and vascular resection associated with arterial reconstruction.
  • They were divided into 3 groups according to tumor location: Cervical (14), lower limbs (13), and Abdomen (9).
  • RESULTS: There were 5 arterial complications: 2 early- and 3 late-stage.
  • The late-stage complications consisted of 1 symptomatic carotid occlusion, 1 occlusion of an axillary-carotid graft, and 1 occlusion of a branch of the aortobifemoral graft, all without sequelae.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Complications. Reconstructive Surgical Procedures. Survival Analysis. Treatment Outcome. Vascular Patency. Vascular Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924326.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


54. Oh HK, Chambers MS, Martin JW, Lim HJ, Park HJ: Osteoradionecrosis of the mandible: treatment outcomes and factors influencing the progress of osteoradionecrosis. J Oral Maxillofac Surg; 2009 Jul;67(7):1378-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The patients whose ORN was associated with an early-stage tumor or preirradiation extraction had a favorable response to conservative treatment.
  • However, those who had an advanced primary tumor, had continued smoking and drinking after radiotherapy, had received palliative radiotherapy or a radiation dose of more than 6,000 rads, and who had an orocutaneous fistula, a pathologic fracture, swelling, or trismus had a poor response to conservative treatment.
  • CONCLUSIONS: The results of the present study have indicated that several factors (ie, the stage of the primary tumor, signs of ORN) can influence the progress of ORN.
  • [MeSH-minor] Adult. Aged. Debridement. Female. Fractures, Spontaneous / etiology. Humans. Hyperbaric Oxygenation. Male. Mandibular Fractures / etiology. Middle Aged. Neoplasm Staging. Oral Hygiene. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Smoking. Surgical Flaps. Tooth Extraction / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531406.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Prasanna VK, Venkataramana NK, Dwarakanath BS, Santhosh V: Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma. J Cancer Res Ther; 2009 Sep;5 Suppl 1:S44-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma.
  • 2-Deoxy-D-glucose (2-DG), an inhibitor of glucose transport and glycolysis, enhances radiation damage selectively in tumor cells by modulating damage response pathways resulting in cell death in vitro and local tumor control.
  • Phase III efficacy trials are currently at an advanced stage.
  • Re-exploratory surgery performed in 13 patients due to persistent symptoms of elevated ICP and mass effect at different follow-up periods revealed extensive tumor necrosis with well-preserved normal brain tissue adjoining the tumor included in the treatment volume as revealed by a histological examination.
  • These observations are perhaps the first clinical evidences for differential effects of 2-DG on tumors and normal tissues in conformity with earlier in vitro and in vivo studies in normal and tumor-bearing mice.
  • [MeSH-major] Brain Neoplasms / therapy. Deoxyglucose / therapeutic use. Glioblastoma / therapy. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Brain / drug effects. Brain / radiation effects. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009294.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 9G2MP84A8W / Deoxyglucose
  •  go-up   go-down


56. Chen X, Li J, Wu K, Han Y, Xu P: Tra2alpha promotes RA induced neural differentiation of P19 cells. Neurochem Res; 2005 Feb;30(2):271-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study demonstrates a high level of the nuclear Transformer 2alpha (Tra2alpha) protein in adult mouse brain relative to other tissues, including muscle, heart, liver, lungs, kidney and small intestine, suggesting the potential importance of Tra2alpha in neural function.
  • The level of Tra2alpha in mouse cerebrum is developmentally regulated, peaking at neonate stage.
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Mice. Mice, Inbred BALB C. Signal Transduction / drug effects. Telencephalon / drug effects. Telencephalon / metabolism. Transfection. Tubulin / metabolism. Up-Regulation / drug effects

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res Mol Brain Res. 1998 Nov 20;62(2):220-3 [9813338.001]
  • [Cites] FEBS Lett. 2000 May 4;473(1):19-23 [10802051.001]
  • [Cites] Cell. 1993 Jul 16;74(1):105-14 [8334698.001]
  • [Cites] Eur J Neurosci. 1999 Mar;11(3):788-802 [10103073.001]
  • [Cites] Genes Dev. 1994 Jul 15;8(14):1703-12 [7958850.001]
  • [Cites] J Cell Biol. 1982 Aug;94(2):253-62 [7107698.001]
  • [Cites] Exp Cell Res. 1986 Jul;165(1):229-42 [3011479.001]
  • [Cites] DNA Cell Biol. 1997 Jun;16(6):679-90 [9212162.001]
  • [Cites] J Neurosci. 2002 Jul 15;22(14):5889-99 [12122051.001]
  • [Cites] J Biol Chem. 1995 Nov 24;270(47):28216-22 [7499316.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):18997-9007 [12649279.001]
  • [Cites] Nature. 1989 Aug 17;340(6234):521-4 [2505080.001]
  • [Cites] Cell. 1988 Dec 23;55(6):1025-35 [3144434.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Feb;220(2):59-63 [9933499.001]
  • [Cites] Cell Biol Int. 2003;27(6):491-6 [12798777.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9004-9 [8799144.001]
  • [Cites] Genomics. 1998 Oct 15;53(2):191-202 [9790768.001]
  • [Cites] Cell. 1998 Apr 3;93(1):139-48 [9546399.001]
  • (PMID = 15895831.001).
  • [ISSN] 0364-3190
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA-Binding Proteins; 0 / Tra2alpha protein, mouse; 0 / Tubulin; 5688UTC01R / Tretinoin
  •  go-up   go-down


57. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C: Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery; 2009 Jul;65(1):153-9; discussion 159-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Gliomas are the most common type of primary intracranial tumor.
  • Although tumor grade predicts the clinical course of most patients, molecular characteristics of individual tumors have emerged as important prognostic factors for patients with gliomas.
  • This study assessed whether CRM1, Ser10-phosphorylated p27, and p27 correlated with each other, with glioma pathological stage, and with patient outcome.
  • METHODS: Immunohistochemical and Western blot analysis were performed in 70 cases of human gliomas and normal brain tissues.
  • [MeSH-major] Brain Neoplasms / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Karyopherins / metabolism. Receptors, Cytoplasmic and Nuclear / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Serine / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574837.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Karyopherins; 0 / Ki-67 Antigen; 0 / Receptors, Cytoplasmic and Nuclear; 0 / exportin 1 protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 452VLY9402 / Serine
  •  go-up   go-down


58. Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Miller JD, Gu CS, Cline KJ, Evans WK, Levine MN: Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med; 2009 Aug 18;151(4):221-8, W-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Among patients with early-stage non-small cell lung cancer (NSCLC), preoperative imaging tests are important in defining surgical candidates.
  • The centralized, computer-generated, variable block size randomization scheme was stratified by treatment center and cancer stage.
  • PATIENTS: Eligible patients were older than 18 years; had histologic or cytologic proof of stage I, II, or IIIA NSCLC on the basis of chest radiography and thoracic CT; and had a tumor considered to be resectable.
  • MEASUREMENTS: The primary outcome was correct upstaging, thereby avoiding stage-inappropriate surgery.
  • CONCLUSION: Preoperative staging with PET-CT and cranial imaging identifies more patients with mediastinal and extrathoracic disease than conventional staging, thereby sparing more patients from stage-inappropriate surgery, but the strategy also incorrectly upstaged disease in more patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / pathology. Brain / radiography. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiopharmaceuticals. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Intern Med. 2009 Dec 15;151(12):JC6-10 [20008746.001]
  • [CommentIn] Ann Intern Med. 2009 Aug 18;151(4):279-80 [19581638.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2009 Aug 18;151(4):I-21 [19581637.001]
  • (PMID = 19581636.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00136890
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


59. Nishizawa S, Kojima S, Teramukai S, Inubushi M, Kodama H, Maeda Y, Okada H, Zhou B, Nagai Y, Fukushima M: Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report. J Clin Oncol; 2009 Apr 10;27(11):1767-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Screening modalities included were whole-body FDG-PET, chest and abdominal computed tomography (CT), brain and pelvic magnetic resonance imaging, several tumor markers, and fecal occult blood testing.
  • Of the 18 detected in the initial screening (six thyroid, four lung, three prostate, three breast, one endometrial, and one thymic), 12 were at stage I and 11 were PET positive.
  • CONCLUSION: While FDG-PET alone is insufficient, whole-body cancer screening with selected modalities including FDG-PET has initial performance supporting possible utility by detecting a wide variety of early-stage cancers with reasonable sensitivity.
  • [MeSH-major] Biomarkers, Tumor / blood. Neoplasms / diagnosis. Neoplasms / prevention & control. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Male. Mass Screening. Middle Aged. Occult Blood. Prospective Studies. Radiopharmaceuticals. Tomography, X-Ray Computed

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Apr 10;27(11):1740-1 [19255306.001]
  • (PMID = 19255324.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


60. Garcia-Lavandeira M, Quereda V, Flores I, Saez C, Diaz-Rodriguez E, Japon MA, Ryan AK, Blasco MA, Dieguez C, Malumbres M, Alvarez CV: A GRFa2/Prop1/stem (GPS) cell niche in the pituitary. PLoS One; 2009;4(3):e4815
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The adult endocrine pituitary is known to host several hormone-producing cells regulating major physiological processes during life.
  • However, not much is known about pituitary cell renewal throughout life and its homeostatic regulation during specific physiological changes, such as puberty or pregnancy, or in pathological conditions such as tumor development.
  • SIGNIFICANCE: Our results suggest the presence in the adult pituitary of a specific niche of cells characterized by the expression of GFRa2, the pituitary-specific protein Prop1 and stem cell markers.
  • [MeSH-minor] Animals. Bromodeoxyuridine / pharmacology. Cell Proliferation. Gene Expression. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Hypopituitarism / metabolism. Mice. Octamer Transcription Factor-3 / metabolism. Pituitary Hormones / metabolism. Rats. Stage-Specific Embryonic Antigens / metabolism. Telomere / ultrastructure. Transcription Factors / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1998 Feb;18(2):147-9 [9462743.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):1111-5 [9609310.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2601-4 [9661653.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2899-911 [9744866.001]
  • [Cites] Neuron. 1999 Feb;22(2):243-52 [10069331.001]
  • [Cites] Neuron. 1999 Feb;22(2):253-63 [10069332.001]
  • [Cites] Nat Genet. 1999 May;22(1):44-52 [10319860.001]
  • [Cites] Acta Anat (Basel). 1951;11(2-3):361-82 [14829142.001]
  • [Cites] Hum Mol Genet. 2004 Nov 15;13(22):2727-35 [15459176.001]
  • [Cites] Dev Biol. 2005 Mar 1;279(1):114-24 [15708562.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):698-710 [15591534.001]
  • [Cites] Endocrinology. 2005 May;146(5):2376-87 [15677762.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):1-12 [15994739.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):166-76 [15916758.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):441-67 [15982921.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3985-98 [15932930.001]
  • [Cites] Mol Endocrinol. 2001 Sep;15(9):1484-95 [11518797.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4529-35 [11549703.001]
  • [Cites] Development. 2002 Jan;129(2):329-37 [11807026.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1879-84 [11932334.001]
  • [Cites] Dev Biol. 2002 May 1;245(1):42-56 [11969254.001]
  • [Cites] Nat Rev Neurosci. 2002 May;3(5):383-94 [11988777.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Mol Endocrinol. 2002 Nov;16(11):2645-56 [12403852.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):461-3 [12612584.001]
  • [Cites] Diabetes. 2003 Aug;52(8):2035-42 [12882920.001]
  • [Cites] Oncogene. 2003 Aug 14;22(34):5261-9 [12917627.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1293-9 [12949502.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Cell. 2004 Mar 19;116(6):769-78 [15035980.001]
  • [Cites] Am J Med Genet A. 2005 Oct 1;138A(2):95-8 [16145681.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):303-11 [16493421.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1654-63 [16384867.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Mol Endocrinol. 2006 Jun;20(6):1378-90 [16556738.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1075-9 [16810242.001]
  • [Cites] J Clin Invest. 2006 Sep;116(9):2442-55 [16932809.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2382-90 [16857898.001]
  • [Cites] Trends Pharmacol Sci. 2007 Feb;28(2):68-74 [17218019.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1743-51 [17062733.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1518-23 [17234709.001]
  • [Cites] EMBO J. 2007 Apr 18;26(8):2015-28 [17380130.001]
  • [Cites] Neuroendocrinology. 2007;85(2):110-30 [17337880.001]
  • [Cites] Development. 2007 Jun;134(11):2001-6 [17507401.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1051-63 [17574020.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3496-506 [10880462.001]
  • [Cites] Cell. 2000 Aug 18;102(4):451-61 [10966107.001]
  • [Cites] Hum Mol Genet. 2001 May 15;10(11):1141-53 [11371507.001]
  • [Cites] Development. 2004 Aug;131(15):3805-19 [15240551.001]
  • [Cites] Cell. 2004 Aug 20;118(4):493-504 [15315761.001]
  • [Cites] J Clin Invest. 2004 Sep;114(6):795-804 [15372103.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5256-65 [15472232.001]
  • [Cites] Endocrinol Jpn. 1977 Jun;24(3):301-5 [913340.001]
  • [Cites] Nat Rev Genet. 2007 Jul;8(7):555-63 [17563758.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):933-63 [17615393.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):2053-65 [17525237.001]
  • [Cites] Semin Cell Dev Biol. 2007 Aug;18(4):559-70 [17509912.001]
  • [Cites] Biol Reprod. 2007 Oct;77(4):723-33 [17625109.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1265-71 [17875653.001]
  • [Cites] Genome Biol. 2007;8(8):R163 [17683608.001]
  • [Cites] Cell. 2008 Jan 25;132(2):299-310 [18243104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2907-12 [18287078.001]
  • [Cites] Genes Dev. 2008 Mar 1;22(5):654-67 [18283121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6332-7 [18436641.001]
  • [Cites] Hepatology. 2008 Jun;47(6):1994-2002 [18454509.001]
  • [Cites] PLoS One. 2008;3(7):e2800 [18665239.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1489-93 [10688798.001]
  • [Cites] Cell Tissue Res. 2000 Mar;299(3):409-15 [10772255.001]
  • [Cites] Endocrinology. 2000 May;141(5):1893-6 [10803600.001]
  • [Cites] Brain Res. 1980 Jun 9;191(2):523-31 [6991054.001]
  • [Cites] Nature. 1984 Oct 4-10;311(5985):469-72 [6207435.001]
  • [Cites] Cell Tissue Res. 1988 Aug;253(2):419-24 [2457446.001]
  • [Cites] Anat Embryol (Berl). 1989;179(5):491-5 [2471422.001]
  • [Cites] Arch Histol Cytol. 1989 Jul;52(3):241-8 [2476166.001]
  • [Cites] Eur J Endocrinol. 1995 Jul;133(1):25-32 [7542980.001]
  • [Cites] Dev Biol. 1995 Dec;172(2):495-503 [8612966.001]
  • [Cites] Cell. 1996 May 31;85(5):721-32 [8646780.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(8):1002-7 [8890999.001]
  • [Cites] Nature. 1996 Nov 28;384(6607):327-33 [8934515.001]
  • (PMID = 19283075.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GFRA2 protein, human; 0 / Glial Cell Line-Derived Neurotrophic Factor Receptors; 0 / Homeodomain Proteins; 0 / Octamer Transcription Factor-3; 0 / Pituitary Hormones; 0 / Prophet of Pit-1 protein; 0 / Stage-Specific Embryonic Antigens; 0 / Transcription Factors; 0 / stage-specific embryonic antigen-4; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC2654029
  •  go-up   go-down


61. Fox SW, Lyon D: Symptom clusters and quality of life in survivors of ovarian cancer. Cancer Nurs; 2007 Sep-Oct;30(5):354-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer has nonspecific symptoms, and no screening tool is available for early diagnosis; therefore, only 19% of ovarian cancers are found at an early stage.
  • Most participants had stage III ovarian cancer, and nearly all (97%) had undergone treatment before the study.
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Multivariate Analysis. Regression Analysis. Severity of Illness Index. Survivors / psychology


62. Bodendorf MO, Haas V, Laberke HG, Blumenstock G, Wex P, Graeter T: Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer; 2009 Apr;64(1):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All had been treated by potentially curative surgical resection of the primary tumor and systematic lymphadenectomy.
  • In all cases, lymphatic metastatic spread was at its earliest stage and only one regional lymph node was involved, 27.0+/-8.9 nodes per patient being examined histologically.
  • 62.5% were at stage IIB, 25.9% at stage IIIA, and 9.8% at stage IIA.
  • Local recurrence occurred in 10.7% of the patients, distant metastasis in 24.1%, and both forms of tumor progression simultaneously in a further 7.1%.
  • Thus 31.2% of the patients developed distant metastases by hematogenous spread (to the brain, bones, lung, adrenal, and liver, in descending order of frequency), mostly within two years of surgery.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790545.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


63. McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, Aldape K: Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res; 2008 Dec 1;14(23):7832-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Paired primary and metastatic tumor samples were obtained from 41 patients who had undergone resection of both primary lung adenocarcinoma and brain metastatic lesions.
  • In multivariable analysis, p-S6 expression was a negative independent predictor of metastasis-free survival after adjustment for tumor stage.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2700-9 [10561344.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):710-7 [16467080.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Eur Respir J. 2001 Oct;18(4):705-19 [11716177.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1216-24 [12128123.001]
  • [Cites] Cell. 2002 Oct 4;111(1):9-12 [12372295.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Feb;4(2):117-26 [12563289.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1070-6 [12631609.001]
  • [Cites] Respir Res. 2002;3:27 [12537604.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] J Korean Med Sci. 2003 Aug;18(4):494-500 [12923324.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):3-7 [14745718.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):430-9 [14739904.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):321-8 [17265080.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2257-67 [17440983.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6325-32 [17616691.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] Cancer Lett. 2004 Oct 28;214(2):157-64 [15363541.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6865-71 [15501963.001]
  • [Cites] Chest. 1992 Apr;101(4):1013-8 [1313349.001]
  • [Cites] BMJ. 1992 Feb 29;304(6826):541-3 [1313719.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94 [15317667.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1530-7 [15735128.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;65:101-27 [11008486.001]
  • (PMID = 19047111.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA070907-040007; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-040007; United States / NCI NIH HHS / CA / P50CA70907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / TTF1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS83486; NLM/ PMC2614348
  •  go-up   go-down


64. Keita M, Kampo MI, Timbo SK, Traoré CB, Diallo M, Doumbia-Singaré K, Ag Mohamed A: [Morbidity of the tumours of the sphere head and neck in Bamako]. Mali Med; 2009;24(3):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Where excluded from the study the patients whose file were not completed and those that have had eye and brain tumours From the data base of the department, a total of 60 cases of tumours were monitored and 25 others cases were excluded according to the criteria.
  • Goiter was the most found benign tumor according to the results of the hystology analysis.
  • In most cases these tumors were diagnosed at an advanced stage.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Mali. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20093222.001).
  • [ISSN] 1993-0836
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mali
  •  go-up   go-down


65. Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, Dunn RL, Wozniak AJ, Kraut MJ, Kalemkerian GP: Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs; 2009 Dec;27(6):571-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since these data suggested that SCLC is the adult solid tumor that is most susceptible to fenretinide, a trial to evaluate the clinical activity of fenretinide in patients with SCLC was considered the definitive test of its clinical potential in adult oncology.
  • Patients with stable, treated brain metastases were eligible.
  • However, after the first stage of enrollment, the response rate did not meet criteria to proceed with full trial accrual.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 May 15;59(10):2493-8 [10344763.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49531-7 [12388538.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:80-6 [8747381.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):179-85 [15744595.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6149-52 [2529028.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4606-13 [14555536.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Treat Rep. 1987 Apr;71(4):391-405 [3548957.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):6036-41 [8261419.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):2036-42 [8410127.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2032-9 [12796365.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1664-70 [11250995.001]
  • [Cites] Exp Cell Res. 1991 Jul;195(1):163-70 [1675998.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1345-55 [9607596.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4282-9 [15514370.001]
  • [Cites] Apoptosis. 2006 Oct;11(10):1677-94 [16850162.001]
  • [Cites] Leukemia. 2002 May;16(5):902-10 [11986953.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1794-801 [10561217.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1674-80 [7473815.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1245-7 [8040893.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5603-10 [7585641.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] J Natl Cancer Inst. 1985 Nov;75(5):871-5 [2932587.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1914-9 [17035399.001]
  • [Cites] Int J Oncol. 1995 Sep;7(3):433-41 [21552857.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 1;96(17):1264-5 [15339958.001]
  • [Cites] Adv Pharmacol. 1995;33:315-47 [7495674.001]
  • [Cites] Cell Growth Differ. 1993 Oct;4(10):799-809 [8274449.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(2):145-50 [9923820.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1859-68 [1717924.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Mar;6(3):323-31 [18377850.001]
  • (PMID = 19225720.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11103-57-4 / Vitamin A; 187EJ7QEXL / Fenretinide
  •  go-up   go-down


66. Hierner R, van Loon J, Goffin J, van Calenbergh F: Free latissimus dorsi flap transfer for subtotal scalp and cranium defect reconstruction: report of 7 cases. Microsurgery; 2007;27(5):425-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The purpose of the paper is to review the results of free latissimus dorsi transfer for scalp and cranium reconstruction in case of large defects with exposed brain tissue, deperiosted cranial bone, and dura that cannot be reconstructed with local flaps or skin grafts.
  • METHODS: Free latissimus dorsi transfer was carried out in an interdisciplinary approach involving neurosurgery and plastic surgery in seven patients with subtotal and total scalp defects (two reconstruction after tumor removal, two reconstructions after longstanding osteitis, 2x tissue break down after irradiation, 1x defect reconstruction after high voltage injury).
  • Reconstruction was carried out with a muscle flap (1x) or a myo-cutaneous flap (6x) in combination with a split thickness skin mesh (1:1.5) graft, done in a single-stage procedure.
  • [MeSH-minor] Adult. Aged. Algorithms. Female. Humans. Male. Middle Aged. Osteitis / surgery. Skin Neoplasms / surgery. Skin Transplantation. Skull Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc.
  • (PMID = 17596862.001).
  • [ISSN] 0738-1085
  • [Journal-full-title] Microsurgery
  • [ISO-abbreviation] Microsurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L: Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med; 2007 Sep;48(9):1442-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively.
  • Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704242.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; RWM8CCW8GP / Octreotide
  •  go-up   go-down


68. Kim YZ, Kim KH, Kim JS, Song YJ, Kim KU, Kim HD: Clinical analysis of patients who survived for less than 3 months after brain metastatectomy. J Korean Med Sci; 2009 Aug;24(4):641-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of patients who survived for less than 3 months after brain metastatectomy.
  • In the patients with brain metastasis (BM), it is impossible to determine who will benefit from surgery because of limited survival.
  • In an attempt to identify optimal candidates for brain metastatectomy, we analyzed patients who survived for <3 months after craniotomy for a single BM lesion.
  • Of the 25 patients, 19 (79%) were of tumor stage IV and had extra-cranial metastasis.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Craniotomy. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Neurol (Paris). 1992;148(6-7):477-87 [1448668.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S24-32; discusssion S1-4 [16237284.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):146-53 [8691861.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):337-44 [8823767.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:184-92 [9032860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):53-63 [9407631.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1044-55; discussion 1055-6 [9588549.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Sep;122(3):548-53 [11547308.001]
  • [Cites] Lung Cancer. 2001 Aug-Sep;33(2-3):143-54 [11551409.001]
  • [Cites] Neurosurgery. 2003 May;52(5):1066-73; discussion 1073-4 [12699548.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1318-26; discussion 1326 [12762877.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2114-20 [14522368.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1705-11 [15073860.001]
  • [Cites] Adv Neurol. 1978;19:579-92 [570349.001]
  • [Cites] Ann Thorac Surg. 1986 Oct;42(4):360-4 [3767508.001]
  • [Cites] Respiration. 1987;51(3):170-8 [3037658.001]
  • [Cites] Ann Thorac Surg. 1988 Jul;46(1):24-8 [3289517.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):300-4 [1648994.001]
  • [Cites] Ann Oncol. 1999 Jul;10(7):753-9 [10470420.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 2:S253-7 [15552807.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):31-42 [16215814.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):605-16 [7674008.001]
  • (PMID = 19654946.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2719185
  • [Keywords] NOTNLM ; Brain Metastasis / Metastatectomy / Prognosis / Surgical Candidate / Survival
  •  go-up   go-down


69. Marsh J, Mukherjee P, Seyfried TN: Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res; 2008 Dec 1;14(23):7751-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma.
  • PURPOSE: Malignant astrocytomas exhibit constitutive Akt phosphorylation due to reduced phosphatase and tensin homologue (PTEN) tumor suppressor expression or to increased growth factor receptor tyrosine kinase activation.
  • Although dietary restriction (DR) reduces glycolysis and manages early-stage astrocytoma growth, no prior studies have identified the mechanisms involved or determined if DR can also manage late-stage tumor growth.
  • EXPERIMENTAL DESIGN: The effects of a late-onset intermittent DR feeding paradigm were examined in adult C57BL/6J mice bearing the syngeneic CT-2A malignant astrocytoma grown orthotopically or subcutaneously.
  • RESULTS: In contrast to contralateral normal brain, CT-2A was PTEN/TSC2 protein deficient; exhibited constitutive Akt, mTOR, and BAD phosphorylation; and overexpressed insulin-like growth factor-I (IGF-I), IGF-I receptor, hypoxia-inducible transcription factor-1alpha (HIF-1alpha), type 1 glucose transporter protein (GLUT1), and pyruvate kinase.
  • DR initiated 10 to 14 days after tumor implantation (late onset) reduced CT-2A growth, delayed malignant progression, and significantly extended survival.
  • [MeSH-major] Astrocytoma / diet therapy. Brain Neoplasms / diet therapy. PTEN Phosphohydrolase / deficiency. Proto-Oncogene Proteins c-akt / metabolism. Tumor Suppressor Proteins / deficiency

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047102.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102135; United States / NINDS NIH HHS / NS / NS 055195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


70. Thöm I, Schult-Kronefeld O, Burkholder I, Schuch G, Andritzky B, Kastendieck H, Edler L, Wagener C, Bokemeyer C, Schumacher U, Laack E: Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. Anticancer Res; 2009 Jan;29(1):249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant positive correlation was found between CEACAM-1 expression on cells of the primary tumor, lymph node metastases (p < 0.005) and hematogenous metastases (p = 0.03).
  • CEACAM-1 expression did not correlate with stage, gender, grading or patients' age.
  • Compared to patients with tumors not expressing CEACAM-1, patients with a CEACAM-1-expressing tumor had a shorter median overall survival (21 vs. 28 months) and progression-free survival (11.7 vs. 16.3 months).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / immunology. Brain Neoplasms / secondary. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331157.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  •  go-up   go-down


71. Sen C, Shrivastava R, Anwar S, Triana A: Lateral transcondylar approach for tumors at the anterior aspect of the craniovertebral junction. Neurosurgery; 2010 Mar;66(3 Suppl):104-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The location and extent of the tumor were defined, and the postoperative images were studied to determine the degree of resection.
  • Surgery was performed in 1 stage in 19 patients, and the tumor resection in the remaining patients was done in 2 stages.
  • Radical tumor resection was achieved in 17 patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Atlanto-Occipital Joint / pathology. Atlanto-Occipital Joint / radiography. Atlanto-Occipital Joint / surgery. Brain Stem / anatomy & histology. Brain Stem / surgery. Child. Cranial Fossa, Posterior / pathology. Cranial Fossa, Posterior / radiography. Cranial Fossa, Posterior / surgery. Craniotomy / methods. Dura Mater / anatomy & histology. Dura Mater / surgery. Female. Humans. Intraoperative Complications / etiology. Intraoperative Complications / prevention & control. Laminectomy / methods. Male. Middle Aged. Odontoid Process / pathology. Odontoid Process / radiography. Odontoid Process / surgery. Preoperative Care. Spinal Cord / anatomy & histology. Spinal Cord / surgery. Treatment Outcome. Vertebral Artery / anatomy & histology. Vertebral Artery / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173511.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G: Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res; 2008 Mar 1;14(5):1464-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Endothelins and their cell membrane receptors (ET(A)R and ET(B)R) are implicated in neoplastic pathogenesis. atrasentan, a potent, selective ET(A)R antagonist, has a direct effect on tumor proliferation, apoptosis, and angiogenesis.
  • EXPERIMENTAL DESIGN: Chemonaive patients with stage IIIB (malignant pleural effusion) and IV non-small cell lung cancer were enrolled.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Endothelin A Receptor Antagonists. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Pyrrolidines / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316570.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin A Receptor Antagonists; 0 / Pyrrolidines; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; V6D7VK2215 / atrasentan
  •  go-up   go-down


73. Xiao ZJ, Li CL: [Diagnosis and treatment of sarcomatoid renal cell carcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Jan 26;90(4):256-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical stage (TNM) of 10 cases is T1N0M0 1 case, T2N0M0 3 cases, T3N0M0 1 case, T4N0M0 1 case, T2N0M1 3 cases, T4N0M1 1 case.
  • In these 6 cases, 4 cases were diagnosed with pulmonary metastasis, 1 with brain metastasis, and 1 with osseous metastasis, and 1 with inferior vena cava tumor thrombus.
  • The average life span of all 10 cases was 17 months, and cases with advanced stage was 8 months.
  • Otherwise, the average survival time of cases with earlier stage was 30 months, and it was 21 months from diagnosis to metastasis.
  • CONCLUSION: Sarcomatoid renal cell carcinoma is a special type of renal cell carcinoma with features of high malignant and rapid progress.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20356541.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


74. Beschorner R, Mittelbronn M, Mugler M, Meyermann R, Schittenhelm J: Immunohistochemical analysis of CDX2 expression in normal choroid plexus epithelium and choroid plexus tumors. Histol Histopathol; 2009 12;24(12):1507-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the intestine, Wnt signaling represses the expression of the tumor suppressor gene CDX2 via SOX9, a transcription factor, which is also expressed in the choroid plexus.
  • Recently, an inverse correlation between CDX2 expression and tumor grade, tumor stage and lymph node metastasis in colorectal adenocarcinomas has been reported.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. CDX2 Transcription Factor. Case-Control Studies. Child. Child, Preschool. Epithelium / metabolism. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795349.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


75. Chuang KL, Liaw CC, Ueng SH, Liao SK, Pang ST, Chang YH, Chuang HC, Chuang CK: Mixed germ cell tumor metastatic to the skin: case report and literature review. World J Surg Oncol; 2010;8:21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed germ cell tumor metastatic to the skin: case report and literature review.
  • Other metastatic sites include the lung, liver, brain, adrenal glands, gastrointestinal tract and spleen.
  • CASE PRESENTATION: A 19-year old male was diagnosed testicular mixed germ cell tumor with initial presentation of cutaneous metastasis at scalp and upper abdomen.
  • CONCLUSIONS: For advanced stage testicular cancer, cisplatin-based chemotherapy is still effective to achieve partial response.
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 2001 Feb;67(2):117-20 [11236220.001]
  • [Cites] Clin Exp Dermatol. 2002 Jan;27(1):64-5 [11952675.001]
  • [Cites] Int J Urol. 2003 Feb;10(2):103-4 [12588608.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 May;18(3):386-7 [15096171.001]
  • [Cites] Urology. 2004 Jun;63(6):1021-6 [15183939.001]
  • [Cites] J Cutan Pathol. 2004 Jul;31(6):419-30 [15186430.001]
  • [Cites] J Cutan Pathol. 2010 Apr;37(4):486-90 [19469863.001]
  • [Cites] Vopr Onkol. 1981;27(4):70-3 [7195101.001]
  • [Cites] Cancer. 1982 Aug 1;50(3):548-51 [6284333.001]
  • [Cites] Hinyokika Kiyo. 1983 Feb;29(2):155-68 [6687145.001]
  • [Cites] Cutis. 1987 Feb;39(2):119-21 [3829718.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Urology. 2006 Apr;67(4):846.e15-7 [16600346.001]
  • [Cites] J Urol. 1976 Nov;116(5):593-7 [988197.001]
  • (PMID = 20331874.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2851696
  •  go-up   go-down


76. Fléchon A, Culine S, Théodore C, Droz JP: Pattern of relapse after first line treatment of advanced stage germ-cell tumors. Eur Urol; 2005 Dec;48(6):957-63; discussion 963-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of relapse after first line treatment of advanced stage germ-cell tumors.
  • Thirty-five (36.4%) patients had serum tumor marker levels (AFP, hCG and LDH) normal values.
  • Sites of relapse were: abdominal in 47 (49%) patients, thoracic in 17 (17.7%), thoraco-abdominal in 15 (15.6%), and brain in 8 (8.3).
  • All patients with brain metastases at relapse and those who obtained sCR after chemotherapy relapsed within 8 months of follow-up.
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Biopsy, Needle. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Follow-Up Studies. France. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Urologic Surgical Procedures, Male / methods

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084010.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


77. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, Charest A: Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A; 2009 Feb 24;106(8):2712-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.
  • Glioblastoma multiforme (GBM) is a highly lethal brain tumor for which little treatment is available.
  • The epidermal growth factor receptor (EGFR) signaling pathway is thought to play a crucial role in GBM pathogenesis, initiating the early stages of tumor development, sustaining tumor growth, promoting infiltration, and mediating resistance to therapy.
  • Consistent with this, we show here that concomitant activation of wild-type and/or mutant (vIII) EGFR and ablation of Ink4A/Arf and PTEN tumor suppressor gene function in the adult mouse central nervous system generates a fully penetrant, rapid-onset high-grade malignant glioma phenotype with prominent pathological and molecular resemblance to GBM in humans.
  • Studies of the activation of signaling events in these GBM tumor cells revealed notable differences between wild-type and vIII EGFR-expressing cells.
  • We show that wild-type EGF receptor signals through its canonical pathways, whereas tumors arising from expression of mutant EGFR(vIII) do not use these same pathways.
  • Our findings provide critical insights into the role of mutant EGFR signaling function in GBM tumor biology and set the stage for testing of targeted therapeutic agents in the preclinical models described herein.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72 [17646646.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Ann Oncol. 2001 Jun;12(6):745-60 [11484948.001]
  • [Cites] Genesis. 2002 Feb;32(2):148-9 [11857804.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):636-7 [16079829.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):867-74 [16424019.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71 [16609043.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):120-39 [16889899.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):378-81 [17255257.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):112-6 [17317137.001]
  • [Cites] Science. 2007 Oct 12;318(5848):287-90 [17872411.001]
  • (PMID = 19196966.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL081170; United States / NCI NIH HHS / CA / U54 CA119349; United States / NHLBI NIH HHS / HL / K08HL081170
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2650331
  •  go-up   go-down


78. Gauwerky KJ, Ehrenfeld M, Bakos RM, Volkenandt M, Ruzicka T, Berking C: [A rare case of local relapsing oral melanoma]. J Dtsch Dermatol Ges; 2010 Aug;8(8):614-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma of the oral mucosa is an extremely rare tumor.
  • At the time of diagnosis most melanomas are in an advanced stage because of few clinical signs.
  • Eventually, the patient died from brain metastases.
  • [MeSH-minor] Adult. Female. Humans. Rare Diseases / pathology. Rare Diseases / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163505.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Kishi K, Homma S, Takaya H, Miyamoto A, Sakamoto S, Kurosaki A, Motoi N, Yoshimura K: [A clinical study of advanced large cell neuroendocrine carcinoma]. Nihon Kokyuki Gakkai Zasshi; 2006 Aug;44(8):556-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the clinical manifestations, tumor markers, and treatment of these patients.
  • As for tumor markers, the levels of progastrin-releasing peptide (proGRP) and neuron-specific enolase (NSE) were elevated in six patients (67%) and five patients (56%), respectively.
  • The diagnosis of LCNEC was made based on the resected specimens in 8 patients including resection of brain metastasis in 1 and CT-guided needle biopsy in 1.
  • One patient was stage IIIA, 1 was stage IIIB, 3 were stage IV, and 4 had postoperative recurrence.
  • Treatment included chemotherapy alone in 7 patients, chemotherapy plus whole brain radiation in 1, and postoperative radiotherapy in 1.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972612.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin
  •  go-up   go-down


80. Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ, Garin-Chesa P: Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun; 2006;6:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis.
  • Endosialin is a C-type lectin-like cell surface receptor of unknown function, with a distinctive pattern of endothelial expression in newly formed blood vessels in human cancers.
  • To advance these studies we have generated an antibody to the extracellular domain of mouse endosialin and mapped protein expression from embryonic day E10.0 to the adult stage, complemented by mRNA quantification and co-typing for standard endothelial markers.
  • First, endosialin protein is restricted to vascular endothelium and fibroblast-like cells in developing organs, and largely disappears in the adult.
  • For instance, in the E10.0 embryo, endosialin is prominent in the endothelium of the dorsal aorta and, from E11.0 to E14.5, in vessels sprouting from the dorsal aorta, in perineural vascular plexuses, and in brain capillaries.
  • The endosialin protein persists in the stromal fibroblasts of the adult uterus.
  • Finally, in subcutaneous cancer xenograft models endosialin re-appears in the host-derived tumor stroma, both in neo-angiogenic vascular endothelium and in activated stromal fibroblasts.
  • [MeSH-minor] Animals. Animals, Newborn. Antibodies / metabolism. Embryonic Development. Immunohistochemistry. Mice. Mice, Inbred C57BL. Tumor Cells, Cultured

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875435.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD; 0 / Neoplasm Proteins; 0 / tumor endothelial marker 1, mouse
  •  go-up   go-down


81. Yadav BS, Sharma SC, Singh R, Singh G, Kumar V: Postmastectomy radiation and survival in patients with breast cancer. J Cancer Res Ther; 2007 Oct-Dec;3(4):218-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On univariate analyses, factors affecting LRR were age < 40 years (0.019), tumor stage ( P = 0.001 ), grade ( P = 0.027 ), pathological nodal status ( P ), deep resection plane (0.041), ER/PR status ( P = 0.032 ) and postmastectomy radiation therapy (PMRT) ( P ).
  • Factors affecting distant metastases were age < 40 years (0.005), tumor stage ( P ), grade ( P = 0.0007 ), pathological nodal status ( P ), extra capsular extension (ECE) ( P = 0.002 ), hormonal therapy ( P ) and PMRT ( P ).
  • Factors affecting OS were tumor stage ( P ), grade ( P = 0.0001 ), pathological nodal status ( P ), ECE ( P = 0.002 ) ER/PR status ( P = 0.008 ), hormonal therapy ( P = 0.001 ) and PMRT ( P = 0.004 ).
  • On multivariate analysis, factors affecting LRR were age ( P = 0.001 ), tumor stage ( P = 0.021 ), deep resection plane (0.003), ECE ( P = 0.022 ) and PMRT ( P = 0.047 ).
  • Factors affecting OS were menopausal status ( P = 0.017 ), tumor stage ( P = 0.029 ), pathological nodal status ( P = 0.011 ) and PMRT ( P = 0.002 ).
  • Other factors of prognostic importance were menopausal status, tumor stage and pathological nodal status.
  • [MeSH-minor] Adult. Aged. Brain Stem Neoplasms / radiotherapy. Brain Stem Neoplasms / secondary. Brain Stem Neoplasms / surgery. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / radiotherapy. Carcinoma, Lobular / secondary. Carcinoma, Lobular / surgery. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18270397.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


82. Wang T, Sun YE, Yao SL, Yu CH, Yin DY, Tian JH: [Value of carbon-11 choline positron emission tomography in patients with pulmonary abnormalities]. Zhonghua Wai Ke Za Zhi; 2006 Mar 15;44(6):405-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three bronchial alveolar carcinoma, 2 metastatic tumor from kidney and colon, 3 fibrous nodules, 1 cryptococcosis, 1 hamartoma and 1 sclerosing hemangioma showed nothing abnormal in PET scans.
  • In 5 cases suspected brain metastases CH-PET identified 2 cases positive correctly.
  • CH-PET can evaluate N stage effectively in patients with lung cancer.
  • CH-PET can depict brain metastases accurately.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carbon Radioisotopes. Choline. Female. Humans. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638358.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; N91BDP6H0X / Choline
  •  go-up   go-down


83. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • METHODS: Tumor registry data were collected between 1994-1996 on 11 primary tumor sites and 15 metastatic sites from 4399 patients.
  • A single organ was the dominant source of metastases in 7 sites: axillary lymph node from the breast (97%), intestinal lymph node from the colon (84%), thoracic lymph node from the lung (66%), brain from the lung (64%), mediastinal lymph node from the lung (62%), supraclavicular lymph node from the breast (51%), and adrenal gland from the lung (51%).
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Tarasewicz A, Debska-Slizień A, Konopa J, Zdrojewski Z, Rutkowski B: Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc; 2009 Nov;41(9):3677-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have presented a case of a 47-year-old female TSC patient with multisystem involvement (skin, brain, lungs, and kidneys), who developed end-stage renal disease ESRD due to angiomyolipomas with subsequent bilateral nephrectomy.
  • Brain, chest, and abdominal cavity computed tomography images remained stable.
  • [MeSH-minor] Adult. Angiofibroma / complications. Facial Neoplasms / complications. Female. Humans. Immunosuppressive Agents / therapeutic use. Methylprednisolone / therapeutic use. Mutation. Tacrolimus / therapeutic use. Tumor Suppressor Proteins / genetics


85. Attardo A, Fabel K, Krebs J, Haubensak W, Huttner WB, Kempermann G: Tis21 expression marks not only populations of neurogenic precursor cells but also new postmitotic neurons in adult hippocampal neurogenesis. Cereb Cortex; 2010 Feb;20(2):304-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tis21 expression marks not only populations of neurogenic precursor cells but also new postmitotic neurons in adult hippocampal neurogenesis.
  • We here investigated if the expression pattern of Tis21 also correlates with the generation of new neurons in the adult hippocampus.
  • We used Tis21 knock-in mice expressing green fluorescent protein (GFP) and studied Tis21-GFP expression together with markers of adult hippocampal neurogenesis in newly generated cells.
  • We found that Tis21-GFP 1) was absent from the radial glia-like putative stem cells (type-1 cells), 2) first appeared in transient amplifying progenitor cells (type-2 and 3 cells), 3) did not colocalize with markers of early postmitotic maturation stage, 4) was expressed again in maturing neurons, and 5) finally decreased in mature granule cells.
  • Our data show that, in the course of adult neurogenesis, Tis21 is expressed in a phase additional to the one of the embryonic neurogenesis.
  • This additional phase of expression might be associated with a new and different function of Tis21 than during embryonic brain development, where no Tis21 is expressed in mature neurons.
  • Tis21 can thus serve as new marker for key stages of adult neurogenesis.
  • [MeSH-major] Hippocampus / growth & development. Hippocampus / metabolism. Immediate-Early Proteins / genetics. Neurogenesis / genetics. Neurons / metabolism. Stem Cells / metabolism. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Neurosci. 2008 Aug;11(8):888-93 [18587391.001]
  • [Cites] PLoS Biol. 2008 Oct 7;6(10):e246 [18842068.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1797-815 [10669755.001]
  • [Cites] Nature. 2002 Feb 28;415(6875):1030-4 [11875571.001]
  • [Cites] J Neurosci Res. 2002 Nov 1;70(3):327-34 [12391592.001]
  • [Cites] Development. 2003 Jan;130(2):391-9 [12466205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11866-72 [12923297.001]
  • [Cites] J Comp Neurol. 2003 Dec 1;467(1):1-10 [14574675.001]
  • [Cites] Eur J Neurosci. 2003 Nov;18(10):2707-12 [14656319.001]
  • [Cites] Mol Cell Neurosci. 2003 Nov;24(3):603-13 [14664811.001]
  • [Cites] Eur J Neurosci. 2004 Jan;19(2):234-46 [14725617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3196-201 [14963232.001]
  • [Cites] J Neurosci. 2004 Mar 31;24(13):3355-69 [15056715.001]
  • [Cites] Nature. 2004 May 13;429(6988):184-7 [15107864.001]
  • [Cites] Neuron. 2004 May 27;42(4):535-52 [15157417.001]
  • [Cites] Trends Neurosci. 2004 Aug;27(8):447-52 [15271491.001]
  • [Cites] Neurosci Lett. 2004 Oct 7;369(1):24-7 [15380301.001]
  • [Cites] J Comp Neurol. 1975 Jan 15;159(2):149-75 [1112911.001]
  • [Cites] J Comp Neurol. 1987 Oct 22;264(4):449-79 [3680638.001]
  • [Cites] Exp Neurol. 1990 Jan;107(1):23-35 [2295317.001]
  • [Cites] J Comp Neurol. 1990 Nov 15;301(3):365-81 [2262596.001]
  • [Cites] Cell Calcium. 1990 Oct;11(9):599-602 [2285928.001]
  • [Cites] Development. 1992 Sep;116(1):201-11 [1483388.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Mech Dev. 1994 Aug;47(2):127-37 [7811636.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):482-6 [8944033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4639-44 [10200315.001]
  • [Cites] PLoS One. 2008;3(6):e2388 [18545663.001]
  • [Cites] Neuroscience. 2008 Jun 23;154(2):521-9 [18502050.001]
  • [Cites] Eur J Neurosci. 2005 Jan;21(1):1-14 [15654838.001]
  • [Cites] J Neurosci. 2005 Jul 13;25(28):6533-8 [16014714.001]
  • [Cites] Annu Rev Neurosci. 2005;28:223-50 [16022595.001]
  • [Cites] Neuron. 2005 Sep 15;47(6):803-15 [16157276.001]
  • [Cites] J Neurosci. 2005 Nov 9;25(45):10366-8 [16280573.001]
  • [Cites] Mol Cell Neurosci. 2006 Aug;32(4):344-55 [16828306.001]
  • [Cites] Glia. 2006 Dec;54(8):805-14 [16958090.001]
  • [Cites] BMC Neurosci. 2006;7:77 [17105671.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):168-76 [17151600.001]
  • [Cites] Nat Neurosci. 2007 Mar;10(3):355-62 [17277773.001]
  • [Cites] Neuron. 2007 May 24;54(4):559-66 [17521569.001]
  • [Cites] Eur J Neurosci. 2007 May;25(9):2591-603 [17466019.001]
  • [Cites] Cell Tissue Res. 2007 Sep;329(3):409-20 [17541643.001]
  • [Cites] J Neurosci. 2007 Nov 21;27(47):12764-74 [18032648.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20558-63 [18077357.001]
  • [Cites] J Neurosci. 2008 Apr 2;28(14):3707-17 [18385329.001]
  • [Cites] Neural Dev. 2008;3:13 [18507846.001]
  • (PMID = 19482889.001).
  • [ISSN] 1460-2199
  • [Journal-full-title] Cerebral cortex (New York, N.Y. : 1991)
  • [ISO-abbreviation] Cereb. Cortex
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Btg2 protein, mouse; 0 / Immediate-Early Proteins; 0 / Microtubule-Associated Proteins; 0 / Neuropeptides; 0 / Recombinant Fusion Proteins; 0 / SOXB1 Transcription Factors; 0 / Sox2 protein, mouse; 0 / Tumor Suppressor Proteins; 0 / doublecortin protein; 147336-22-9 / Green Fluorescent Proteins; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC2803732
  •  go-up   go-down


86. Le Scodan R, Stevens D, Brain E, Floiras JL, Cohen-Solal C, De La Lande B, Tubiana-Hulin M, Yacoub S, Gutierrez M, Ali D, Gardner M, Moisson P, Villette S, Lerebours F, Munck JN, Labib A: Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol; 2009 Mar 20;27(9):1375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Several studies suggest that surgical excision of the primary tumor improves survival among patients with stage IV breast cancer at diagnosis.
  • Demographic data, tumor characteristics, metastatic sites, and treatments were prospectively recorded.
  • LRT consisted of exclusive LRR in 249 patients (78%), surgery of the primary tumor with adjuvant LRR in 41 patients (13%), and surgery alone in 30 patients (9%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Nov 1;27(31):e179; author reply e180 [19738108.001]
  • (PMID = 19204198.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Daveau C, Stevens D, Brain E, Berges O, Villette S, Moisson P, Gardner M, De la Lande B, Lasry S, Labib A, Le Scodan R: Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy? Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
  • Survival was poorer among patients who did not have a pathologic complete primary tumor response (hazard ratio, 3.05; 95% confidence interval, 1.17-7.99) and in patients with N1 to N2 clinical status at diagnosis (hazard ratio = 2.24; 95% confidence interval, 1.15-4.36).
  • [MeSH-minor] Adult. Aged. Anthracyclines / therapeutic use. Axilla. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Radiotherapy Dosage. Regression Analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20171795.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


88. Samii M, Gerganov V, Samii A: Improved preservation of hearing and facial nerve function in vestibular schwannoma surgery via the retrosigmoid approach in a series of 200 patients. J Neurosurg; 2006 Oct;105(4):527-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete tumor removal was achieved in 98% of patients.
  • CONCLUSIONS: The goal of VS treatment should be total removal in one stage and preservation of neurological function, as they determine a patient's quality of life.
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebellopontine Angle / surgery. Cochlear Nerve / physiopathology. Electromyography. Evoked Potentials, Auditory, Brain Stem / physiology. Facial Muscles / innervation. Facial Nerve / physiopathology. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Monitoring, Intraoperative. Neurologic Examination. Retrospective Studies

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2006 Oct;105(4):526; discussion 526 [17044552.001]
  • [CommentIn] J Neurosurg. 2007 May;106(5):937-8; author reply 938 [17542547.001]
  • (PMID = 17044553.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Pierga JY, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, Marty M: A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat; 2010 Jul;122(2):429-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by docetaxel with the randomized addition of celecoxib in HER2 negative patients or trastuzumab in HER2 positive patients.
  • From May 2004 till October 2007, 340 patients with stage II and III breast adenocarcinoma, ineligible for breast conserving surgery, received eight sequential three weekly cycles of EC-D [epirubicin (75 mg/m(2))-cyclophosphamide (750 mg/m(2)) for four cycles followed by docetaxel (100 mg/m(2)) for four cycles].
  • Celecoxib is not likely to improve pCR rates in addition to EC-D in patients with HER2-negative tumor.
  • In HER2-positive tumor patients, trastuzumab added to ECD leads to increased pCR rates.
  • It was the only combination to deserve further study according to the two-stage Fleming's design used in this trial.
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Celecoxib. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Disease-Free Survival. Epirubicin / administration & dosage. Female. France. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage. Taxoids / administration & dosage. Therapeutics. Time Factors. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20480225.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN10059974
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; JCX84Q7J1L / Celecoxib; P188ANX8CK / Trastuzumab
  •  go-up   go-down


90. Schittenhelm J, Psaras T, Meyermann R, Honegger J, Beschorner R: Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. Folia Neuropathol; 2010;48(2):75-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Previous studies have shown an inverse correlation between the expression of CDX2 (also known as CDX3) and tumour grade, stage and lymph node dissemination in colorectal adenomas and adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20602288.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


91. Bruggink AH, de Jonge N, van Oosterhout MF, Van Wichen DF, de Koning E, Lahpor JR, Kemperman H, Gmelig-Meyling FH, de Weger RA: Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. J Heart Lung Transplant; 2006 Feb;25(2):174-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device.
  • BACKGROUND: Brain natriuretic peptide (BNP) is a cardiac neurohormone synthesized in cardiac ventricles as a result of increased wall stress.
  • Left ventricular assist device (LVAD) support in patients with end-stage heart failure results in reduced wall stress and therefore may change BNP levels in the heart.
  • METHODS: BNP plasma levels were measured in 17 patients with end-stage HF before LVAD implantation and at 1 week, 1 month, and 3 months after LVAD support.
  • [MeSH-major] Heart Failure / metabolism. Heart Failure / therapy. Heart Ventricles / physiopathology. Heart-Assist Devices. Myocardium / chemistry. Myocardium / metabolism. Natriuretic Peptide, Brain / blood
  • [MeSH-minor] Adult. Antigens, CD45 / analysis. Biopsy. Endothelium, Vascular / metabolism. Female. Gene Expression Regulation. Humans. Immunohistochemistry. Macrophages / metabolism. Male. Middle Aged. Myocytes, Cardiac / metabolism. Polymerase Chain Reaction. RNA, Messenger / analysis. RNA, Messenger / genetics. T-Lymphocytes / chemistry. T-Lymphocytes / immunology. T-Lymphocytes / metabolism. T-Lymphocytes / pathology. Tumor Necrosis Factor-alpha / analysis. Tumor Necrosis Factor-alpha / physiology. Ventricular Remodeling / physiology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446217.001).
  • [ISSN] 1557-3117
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 114471-18-0 / Natriuretic Peptide, Brain; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


92. Chen GY, Jiang GL, Wang LJ, Qian H, Fu XL, Yang H, Wu KL, Zhao S: Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial. Int J Radiat Oncol Biol Phys; 2005 Jan 1;61(1):70-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To fit the situation of developing countries, where supportive care is not sufficient, a modified combined therapy of cisplatin/etoposide (EP) and hyperfractionated accelerated radiation therapy (HART) was conducted as a Phase II trial for limited-stage small-cell lung cancer (LSCLC) to evaluate the feasibility, toxicity, and tolerance of the combined therapy and to observe its efficacy and patterns of failure.
  • All were limited stage, and the median age was 60 years (range, 25 to 70 years).
  • Forty-four patients suffered distant metastases, 66% of which were in brain.
  • (1) LSCLC patients tolerate HART at 56 Gy in 40 fractions over 4 weeks combined with 6 cycles of EP chemotherapy. (2) Both control of the tumor in the thorax and survival appear superior to conventional fractionated radiation but not as good as that in a study by Turrisi and colleagues. (3) This modified chemoradiation schedule could be recommended to LSCLC patients in developing countries. (4) The lessons learned from our study are (a) higher radiation doses may be needed for better locoregional control, and (b) prophylactic cranial irradiation is necessary for LSCLC patients who show complete response.
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Etoposide / administration & dosage. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Radiotherapy Dosage